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1 Zusammenfassung 
Krankheitsbedingte Anorexie trägt bei akuten und chronischen entzündlichen 
Krankheiten zum Anorexie-Kachexie-Syndroms (ACS) bei. Der Nucleus arcuatus (Arc) 
ist eine Zielstruktur für das orexigene Hormon Ghrelin. Auch die Area Postrema (AP) 
spielt eine wichtige Rolle bei der Kontrolle des Energiehaushalts. Der inflammatorische 
Neuromodulator Stickstoffmonoxid (NO) wird durch die induzierbare NO-Synthase 
(iNOS) gebildet und trägt zur krankheitsbedingten Anorexie bei. Nuclear factor (NF)-κB 
und STAT (janus kinases, signal transducers and activators of transcription) regulieren 
die iNOS Expression. In elektrophysiologischen in vitro Versuchen vermittelte NF-κB im 
Gegegnsatz zu STAT die LPS/NO-abhängige Hemmung orexigener Arc Neurone. 
Ausserdem aktivierte LPS in immunhistologischen Versuchen Endothelzellen in der AP. 
In weiteren elektrophysiologischen und Verhaltensstudien wurde die Wirkung des neuen 
Ghrelin-Agonisten HM01 charakterisiert. HM01 hatte eine dem Ghrelin analoge Wirkung 
auf die neuronale Aktivität im Arc. Darüberhinaus führte eine chronische Verabreichung 
in Ratten zu einer Erhöhung Futteraufnahme und des Körpergewichts. Während die 
funktionelle Bedeutung von NF-κB in der AP noch untersucht werden muss, scheint 
dieser Signaltransduktionsweg orexigenen Faktoren wie dem Ghrelin im Arc entgegen zu 
wirken. Zusammenfassend legen die Resultate nahe, dass eine pharmakologische NF-κB-
Hemmung und eine Behandlung mit HM01 mögliche Therapieansätze  gegen ACS 
darstellen könnten. 
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2 Summary 
Disease-related anorexia contributes to the anorexia-cachexia syndrome (ACS) in acute 
and chronic inflammatory diseases. The arcuate nucleus (Arc) is a target for the 
orexigenic hormone ghrelin. Similar to the ARC the area postrema (AP) also plays a 
pivotal role in the control of energy homeostasis. The inflammatory neuromodulator 
nitric oxide (NO) is produced by the inducible nitric oxide synthase (iNOS) and emerged 
as possible mediator of sickness anorexia. Nuclear factor (NF)-κB and STAT (signal 
transducers and activators of transcription) regulate iNOS gene expression. Using an 
electrophysiological approach we demonstrated that LPS inhibits ghrelin-excited Arc 
neurons via NF-κB but not STAT-dependent induction of iNOS activity. LPS also 
induced NF-κB signaling in vascular cells of the AP as demonstrated by 
immunohistological studies. In electrophysiological and behavioral studies we further 
characterized the action of the novel ghrelin agonist HM01. HM01 mimicked the effect 
of ghrelin on neuronal activity in the Arc and increased food intake and body weight gain 
after chronic administration in rats. While the functional implications of NF-κB signaling 
in the AP need to be further elucidated, an activation of this pathway appears to 
counteract orexigenic stimuli such as ghrelin acting via the Arc. In summary, the current 
findings suggest that pharmacological inhibition of NF-κB and HM01 treatment might 
represent possible therapeutic approaches against sickness-anorexia. 
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3 Introduction 
3.1 Energy homeostasis and control of food intake 
Living organisms rely on energy intake to fulfill their biological functions. Energy 
balance is highly regulated accomplishing stability in body weight. Food intake causes 
short-term discrepancy in energy balance, but the body developed a complex system to 
accurately match total energy intake to energy expenditure in order to maintain body 
weight constant over a long period of time (Schwartz et al., 2000).  
The brain plays a key role in energy homeostasis integrating signals from central and 
peripheral pathways (Woods, 2009). Food intake and energy expenditure are influenced 
by two categories of peripheral signals. One comprises several hormones produced from 
the GI tract and the pancreas (peptide YY, cholecystokinin, glucagone-like peptide-1, 
amylin, etc.) that act as satiation signals and control meal size. The second category 
comprises leptin from white adipose tissue and insulin from the pancreatic B cells, which 
are secreted in proportion to body fat and act in the brain as so-called adiposity signals. 
Satiation and adiposity signals interact in the hypothalamus and in other brain regions, 
particularly the brainstem, to control energy homeostasis (Woods and D'Alessio, 2008). 
 
3.1.1 Role of the arcuate nucleus in the control of food intake 
The arcuate nucleus (Arc) is an important brain structure for the control of food intake 
and energy balance (Suzuki et al., 2010). The Arc is located in the ventral hypothalamus 
around the basal part of the third ventricle, in close proximity to the median eminence 
and the pituitary gland (Chronwall, 1985). Two subpopulations of Arc neurons exert 
opposite effects on food intake and energy balance: in rats neurons co-expressing the 
orexigenic neuropeptide Y (NPY) and agouti related peptide (AgRP) (Broberger et al., 
1998) are located in the ventromedial part of the Arc (ArcM). Neurons co-expressing pro-
opiomelanocortin (POMC) and cocaine- and amphetamine-regulated transcript (CART) 
inhibit feeding and in rats they are predominantly localized in the lateral Arc (ArcL) 
(Broberger et al., 1997). POMC is a precursor of the neurotransmitter α-melanocyte-
stimulating-hormone (αMSH), which reduces food intake acting at melanocortin 3 and 
melanocortin 4 receptors (MC3R and MC4R) (Fan et al., 1997). AgRP is an endogenous 
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antagonist of MC3R and MC4R and therefore counteracts the anorectic activity of POMC 
neurons (Ollmann et al., 1997). NPY stimulates ingestive behavior (Stanley et al., 1986) 
acting on Y receptors and inhibiting POMC neurons (Roseberry et al., 2004). Both 
populations of neurons project to other hypothalamic areas such as paraventricular nuclei 
(PVN), dorsomedial nucleus (DMN), lateral hypothalamic area (LHA), ventromedial 
hypothalamic nucleus (VMN) and other brain areas (Luquet and Magnan, 2009; Schwartz 
et al., 2000; Woods and D'Alessio, 2008). Moreover, the Arc is known to be an important 
target site for the hormones leptin and ghrelin. 
 
Leptin is the product of the ob gene (Zhang et al., 1994) and it is mainly produced in 
white adipose tissue in proportion to total body fat (Margetic et al., 2002). Mutation of 
the ob gene or the leptin receptor (Ob-R) results in hyperphagia and obesity in both 
humans and rodents (Friedman and Halaas, 1998; Montague et al., 1997). The Ob-R is 
expressed in many brain areas involved in energy balance including the Arc, which is the 
most important target site of leptin (Elmquist et al., 1998; Schwartz et al., 1996). In the 
Arc, leptin inhibits NPY/AgRP neurons (Mizuno and Mobbs, 1999; Stephens et al., 1995) 
and it stimulates POMC neurons (Cowley et al., 2001). 
 
Ghrelin is the only known orexigenic peptide hormone, which is secreted into the 
circulation by gastric endocrine cells, i.e. X/A-like cells in rodents and P/D1 cells in 
humans (Date et al., 2000; Inui et al., 2004; Kojima et al., 1999). It is an endogenous 
ligand of the G-protein coupled growth hormone secretagogue receptor (GHS-R) and 
stimulates the release of growth hormone (GH) from the pituitary gland (Kojima et al., 
2001). Ghrelin is a potent orexigenic hormone that leads to increased body weight in 
animals and humans (Asakawa et al., 2001; Wren et al., 2001). Plasma ghrelin levels rise 
pre-prandially and fall post-prandially (Cummings et al., 2001), suggesting a possible 
role of ghrelin as hunger signal triggering meal initiation. The GHS-R is highly expressed 
in 94% of the NPY neurons in the Arc (Willesen et al., 1999). Peripheral administration 
of ghrelin induces Fos expression, a marker for neuronal activation, in NPY-synthesizing 
neurons in the Arc (Wang et al., 2002). As shown by electrophysiological studies ghrelin 
directly activates leptin-inhibited Arc neurons (Traebert et al., 2002), while it indirectly 
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(presynaptically) inhibits POMC neurons in the Arc (Cowley et al., 2003; Riediger et al., 
2003). 
 
3.1.2 The area postrema and food intake control 
The area postrema (AP) is a component of the dorsal vagal complex, a major 
viscerosensory and autonomic center of the medulla oblongata. It is one of the three 
sensory circumventricular organs (sCVOs). sCVOs are specialized brain structures near 
the ventricular spaces in the midline of the brain. They are characterized by dense 
vascularization and lack of a functional blood brain barrier (BBB). Due to the fenestrated 
capillaries they can be reached by humoral factors including peptide hormones that 
cannot passively cross the BBB in other brain areas (Johnson and Gross, 1993; McKinley 
et al., 2003; Price et al., 2008). Due to these properties the AP represents a brain target 
for circulating messengers molecules. The AP was first characterized as chemoreceptor 
trigger zone mediating emetic responses induced by noxious chemical stimuli (Borison 
and Brizzee, 1951; Miller and Leslie, 1994). Subsequent studies showed its role in 
feeding and metabolism, fluid balance and cardiovascular control (Price et al., 2008).  
The AP mediates the anorexigenic effect of the pancreatic hormone amylin, which is co-
secreted with insulin during and after food intake (Butler et al., 1990; Moore and Cooper, 
1991). Amylin dose-dependently reduces meal size in rats (Lutz et al., 1994; Lutz et al., 
1995). The crucial role of the AP as primary target for amylin in the brain has been 
demonstrated in several studies. Surgical removal of the AP blocked the feeding 
inhibitory action of amylin (Lutz et al., 2001; Lutz et al., 1998). In immunohistochemical 
studies peripheral injection of amylin induced c-Fos expression in the AP (Riediger et al., 
2001; Rowland et al., 1997). This neuronal activation is in line with the 
electrophysiological studies, which showed strong excitatory effects induced by amylin 
in the AP in 48% of the recorded neurons (Riediger et al., 2001).  
 
3.2 Disease-related anorexia  
Disease-related anorexia is a clinical symptom in a variety of acute and chronic 
inflammatory diseases such as bacterial, viral and parasitic infections, cancer, acquired 
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immune deficiency syndrome (AIDS), chronic obstructive pulmonary disease (COPD), 
inflammatory bowel disease, chronic renal failure, chronic cardiovascular diseases, 
rheumatoid arthritis and others (Plata-Salaman, 1996). During acute inflammatory 
diseases reduced food intake is considered to be part of the host’s defense mechanisms 
(Hart, 1988). A suppressed hunger feeling eliminates the needs to search food, reducing 
energy expenditure. Furthermore, anorexia reduces the availability of food–derived 
micronutrients, impairing the growth of pathogenic microorganisms (Langhans, 2000). 
Despite these beneficial effects, long-term anorexia during disease delays recovery 
compromising host defense, reduces treatment success and decreases quality of life. 
Moreover, long-term anorexia during chronic diseases contributes to cachexia leading to 
the anorexia-cachexia syndrome (ACS). 
 
3.2.1 The anorexia-cachexia syndrome 
Cachexia is defined as a complex metabolic syndrome associated with underlying illness 
and characterized by loss of muscle with or without loss of fat mass. The prominent 
clinical feature of cachexia is weight loss in adults or growth failure in younger 
individuals. Anorexia and increased muscle protein breakdown are frequently associated 
with inflammatory chronic diseases (Evans et al., 2008). The ACS is present in a variety 
of diseases, including chronic infections, cancer, congestive heart failure, COPD and end-
stage renal disease (Akamizu and Kangawa, 2010; Morley et al., 2006). ACS occurs 
approximately in up to 80% of patients with advanced cancer, particularly gastrointestinal 
and lung cancer. It deteriorates the clinical status leading to increased mortality and a 
decline in quality of life. Muscle wasting results in weakness, which leads to immobility 
and can cause death due to loss of respiratory functions. The ACS itself accounts for 
about 20% of deaths in cancer patients (Gordon et al., 2005; Tisdale, 2002).  
 
3.3 Lipopolysaccharide: a model of inflammation-related anorexia 
Lipopolysaccharides (LPS) constitute a major component of the cell membrane of gram-
negative bacteria. During infections LPS is released after bacteriolysis or during rapid 
bacterial proliferation and represent a target molecule for the immune system (Rietschel 
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et al., 1998). LPS triggers a generalized host defense reaction called “acute phase 
response” (APR), which is characterized by alteration in immune, endocrine, metabolic 
and neural functions (Langhans, 2000, 2007). This pathophysiological response includes 
a pro-inflammatory cytokine response, leukocytosis, fever, anorexia and other behavioral 
responses like inactivity, somnolence and depression. LPS administration is a widespread 
model of inflammation and infection-related anorexia. Based on this model some 
generalizations with respect to other inflammatory diseases are possible, given that the 
pro-inflammatory cytokines triggered by LPS also play a role in the mediation of 
anorexia in other diseases. 
 
3.4 Neuroinflammatory mechanisms in disease-related anorexia and 
ACS 
Cytokines are extracellular messenger molecules that have been associated with 
activation of the immune system and inflammatory responses. Activation of the immune 
system leads to production of pro-inflammatory cytokines that trigger an APR. The 
peripheral immune response triggered by LPS treatment induces cytokines such as 
interleukin-1 (IL-1), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α) and interferon-
γ (IFN-γ) (Jansky et al., 1995; Langhans, 2000). 
Peripherally produced cytokines can act on the central nervous system through different 
mechanisms. They can reach CNS receptors crossing the blood-brain barrier (BBB) 
through active or passive transport or through circumventricular organs, such the AP. 
Moreover, they can act at the level of the brain vasculature without crossing the BBB, 
inducing the release of neuromodulators such as prostanoids or nitric oxide (NO) (Banks, 
2001; Langhans, 2000; Licinio and Wong, 1997). In addition to the peripheral cytokine 
response, immune challenges such as LPS treatment have been shown to induce de novo 
cytokine synthesis in the brain, for example in the AP (Breder et al., 1994; Goehler et al., 
2006; Konsman et al., 1999) and in the hypothalamus (Gabellec et al., 1995; Laye et al., 
1994; Turrin et al., 2001). 
Through their central action on the brain, cytokines are important endogenous mediators 
of disease-related anorexia. Several cytokines inhibit feeding after peripheral 
administration (Plata-Salaman, 1996). Disease-related anorexia might at least partly 
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results from a modulation of CNS mechanisms that are involved in the physiological 
control of feeding. Cytokines can directly change the activity of hypothalamic neurons 
involved in the control of food intake (Katafuchi et al., 1997; Langhans, 2000; Plata-
Salaman and ffrench-Mullen, 1994) and several neuropeptides are presumably involved 
in the central mediation of anorexia during an infection. For example, LPS-treatment 
leads to increased POMC and CART mRNA levels in the Arc (Sergeyev et al., 2001). 
Similar to re-feeding and feeding-inhibitory peptides (Riediger et al., 2004), peripheral 
LPS application inhibits fasting-induced neuronal activation in the Arc suggesting an 
interaction between LPS and hunger signals (Becskei et al., 2008).  
Due to the lack of the BBB peripherally circulating substances can directly act on the AP 
(Broadwell and Sofroniew, 1993). Neuronal activation has been shown in the AP after 
immunological challenge with LPS and IL-1 (Brady et al., 1994; Sagar et al., 1995). 
Different studies showed an involvement of the AP in sickness-related anorexia. In fact, 
AP lesions attenuated TNF-α-induced anorexia (Bernstein et al., 1991), and tumor-
induced anorexia and body weight loss (Bernstein et al., 1985). Although lesion of the 
AP did not attenuate acute LPS-induced anorexia (Weingarten et al., 1993), AP-lesioned 
rats did not show social withdrawal (Marvel et al., 2004), indicating that the AP seems to 
be implicated in the modulation of sickness-related behavior. 
 
3.5 Nitric oxide 
There is emerging evidence that the inflammatory neuromodulator NO contributes to 
sickness anorexia. Nitric oxide has been first recognized as a messenger molecule by 
Garthwaite and colleagues (Garthwaite et al., 1988). NO is implicated in a wide range of 
physiological processes acting as intracellular and intercellular messenger molecule. It 
mediates blood vessel relaxation, plays a role in immune function and serves as 
neuromodulator in the central and peripheral nervous system. NO is synthesized from the 
amino acid L-arginine by NO synthase (NOS) (Palmer et al., 1988). 
There are three isoforms of NOS: neuronal NOS (nNOS), endothelial NOS (eNOS) and 
inducible NOS (iNOS). nNOS is expressed in the peripheral and central nervous system 
(Bredt et al., 1990) and it is involved in neurotransmission and in memory and learning 
(Prast and Philippu, 2001). eNOS was first identified in endothelial cells (Pollock et al., 
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1991) but its expression has also been found in other cell types (Forstermann et al., 1998). 
It is involved in smooth muscle relaxation and vascular tone. Both nNOS and eNOS are 
constitutively expressed (Schmidt et al., 1993) and produce NO in a calcium dependent 
manner. iNOS has been first purified from murine macrophages (Hevel et al., 1991) but it 
is also expressed in several other cell types, such as lymphocytes, neutrophils, fibroblasts, 
hepatocytes, vascular smooth muscle and others (Moncada et al., 1991). In the brain 
iNOS is expressed in endothelial cells, neurons, glia and microglial cells (Kuo and 
Schroeder, 1995; Moncada et al., 1991). In contrast to the other two isoform, iNOS is not 
constitutively expressed but its synthesis is induced by inflammatory cytokines, bacterial 
products or infection in different cell types (Aktan, 2004). After induction it remains 
active up to 24 hours and synthesizes 100 times higher amounts of NO than the 
constitutive NOS (Kuo and Schroeder, 1995). 
NO acts as a paracrine messenger with a short half-life of a few seconds. As a lipophilic 
gas it diffuses across membranes and activates the cytoplasmatic enzyme soluble 
guanylate cyclase (sGC). Once activated sGC catalyzes the synthesis of the intracellular 
second messenger cyclic guanosine monophosphate (cGMP), which in turn regulates 
protein phosphorylation, ion channel conductivity and phosphodiesterase activity 
(Schmidt et al., 1993). These mediators regulate several functions in the cells. In neuronal 
tissues cGMP modulates neuronal activity acting on cGMP-dependent protein kinases 
(cGKs), cyclic nucleotide hydrolyzing phosphodiesterases and cyclic nucleotide-gated 
(CNG) cation channels (Feil and Kleppisch, 2008). 
 
3.5.1 Central iNOS signaling in disease-related anorexia 
NO seems to be involved in the inflammatory signaling cascade triggered by LPS and 
might play a pivotal role in the modulation of neuronal activity transducing cytokine 
action. Previous studies have shown a high induction of iNOS messenger RNA in 
vascular, glial and neuronal structures of the rat brain after peripheral LPS administration. 
iNOS expression occurs in the meninges, choroid plexus, median eminence and 
subfornical organ. Interestingly, the Arc and PVN showed a strikingly high induction of 
iNOS (Wong et al., 1996). iNOS expression has also been observed in the PVN and LHA 
of tumor bearing mice (Wang et al., 2005). Unfortunately the Arc has not been analyzed 
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in this study. In electrophysiological in vitro studies NO produced by the artificial NO-
donor sodium nitroprusside (SNP) strongly inhibited Arc neurons that were exited by 
ghrelin (Riediger et al., 2006). These inhibitory effects were mediated by cGMP since 
they were prevented by the specific sGC inhibitor ODQ and mimicked by a membrane 
permeating cGMP analogue. In accordance, immunohistological studies showed a cGMP 
formation induced by SNP, which could also be blocked by ODQ (Riediger et al., 2006). 
These results suggest that pro-inflammatory stimuli with NO as possible mediator 
antagonize orexigenic stimuli that activate Arc neurons. The anorectic role of iNOS-
dependent NO formation in sickness anorexia is supported by the finding that the specific 
and long acting iNOS inhibitor 1400W (Garvey et al., 1997) attenuates the reduction of 
food intake after LPS stimulation (Borner et al., 2012; Riediger et al., 2010). Direct 
evidence for a NO-dependent inhibition of Arc neurons by LPS came from 
electrophysiological studies demonstrating that iNOS blockade by 1400W disinhibits 
ghrelin responsive Arc neurons after in vitro and in vivo stimulation with LPS (Borner et 
al., 2012). Interestingly, third ventricular administration of 1400W almost completely 
blocked LPS-induced anorexia underlining the importance of central NO signaling in 
LPS-dependent suppression of food intake (Borner et al., 2012). 
 
3.5.1.1 iNOS signaling in the AP under inflammatory conditions 
There is evidence for a role of NO signaling in the AP under inflammatory conditions. In 
fact, AP neurons kept in primary cell cultures showed NO responsiveness in calcium 
imaging studies (Wuchert et al., 2009). Moreover, systemic LPS treatment induces iNOS 
mRNA in the AP (Konsman et al., 1999). Pre-treatment with the iNOS inhibitor 
aminoguanidine reduced c-Fos expression in the AP during sepsis induced by cecal 
ligation and puncture suggesting an activation of AP neurons through iNOS-derived NO 
during sepsis (Bruhn et al., 2009).  
 
3.5.2 Transcriptional regulation of iNOS gene expression 
The regulation of iNOS transcription is the main regulatory step to control iNOS activity 
(Kleinert et al., 2003). The promoter regions of the iNOS gene have been studied in 
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humans, mice, rats and birds and several binding sequences for transcription factors have 
been identified (Rao, 2000). Activation of the transcription factors nuclear factor (NF)-
κB and the janus kinase, signal transducers and activators of transcription pathway 
(JAK/STAT) seem to be essential in the regulation of iNOS expression in most cells 
(Kleinert et al., 2003; Pautz et al., 2010). 
 
3.5.2.1 Nuclear factor κB (NF-kB) 
NF-κB is an important inducible transcription factor activated by different stimuli, 
amongst others, by pro-inflammatory cytokines and LPS (Hayden and Ghosh, 2004; 
Perkins, 2007). It is involved in a variety of biological processes like innate and adaptive 
immunity, inflammation, cellular stress responses, cell adhesion, apoptosis and 
proliferation. NF-κB is a member of the rel family of proteins (Ghosh et al., 1998; Verma 
et al., 1995). It is present in the cytosol of unstimulated cells as homo- or heterodimers of 
the subunits p50 and p65, bound to inhibitory κB (IκB) proteins. The binding to IκB 
protein maintains NF-κB in an inactivate state preventing its translocation to the nucleus. 
IκBα plays a pivotal role in the regulation of NF-κB activity. LPS, IFNγ and TNFα 
activate the inhibitor kappa B kinase (IKK) that phosphorylates the IκB-NF-κB complex. 
Phosphorylated IκB proteins are then ubiquinated and degraded, and the liberated NF-κB 
dimers can translocate into the nucleus to regulate target gene expression (Ghosh et al., 
1998; Hayden and Ghosh, 2004).  
NF-κB fulfills a pivotal role in early events of innate immune response through Toll-like 
receptor (TLR) signaling pathways. TLRs recognize specific patterns of microbial 
components and TLR4 has been shown to recognize LPS (Takeda et al., 2003). TLR4 is 
thus responsible for triggering NF-κB pathway activation in response to immune 
challenge with LPS (Nguyen et al., 2002). TLR4 has been shown to be constitutively 
expressed in CVOs, for example in the AP, and other brain areas such as in the arcuate 
nucleus. In the AP TLR4 expression is even up-regulated after LPS stimulation. 
(Laflamme and Rivest, 2001).  
LPS treatment in mice led to NF-κB activation in the Arc, whereas in the AP nuclear 
translocation of NF-κB was observed after immune challenge with IL-1β (Jang et al., 
2010; Nadjar et al., 2003). ICV administration of the NF-κB inhibitor Bay 11-7085 
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significantly blocked the feeding inhibitory effect of systemic LPS treatment (Jang et al., 
2010). Moreover, inactivation of the central NF-κB signaling with ICV injection of a NF-
κB inhibitor significantly blocked the behavioral effects of IL-1β treatment, such as 
decreased food intake, locomotor activity and social interaction (Nadjar et al., 2005).  
These data support a role of NF-κB signaling in the transmission of immune signals from 
the periphery to the brain and suggest an involvement of NF-κB in the Arc and AP during 
illness-anorexia and other related symptoms. However, the specific involvement of NF-
κB in LPS/NO-dependent effects on neuronal function in the Arc and have not yet been 
investigated. Moreover it is not known if NF-κB signaling mediates inflammatory signals 
acting via the AP. 
 
3.5.2.2 Janus kinase, signal transducers and activators of transcription pathway 
(JAK-STAT) 
Several studies have underlined the involvement of STAT signaling in the regulation of 
iNOS expression (Dell'Albani et al., 2001; Doi et al., 2002; Kim et al., 2002). The JAK-
STAT pathway is an intracellular signaling cascade that transduces signals from 
transmembrane receptors to the nucleus to activate gene expression. In mammals there 
are seven STAT genes. In absence of stimulation, STAT proteins are inactive and 
localize in the cytoplasm. STATs are activated by various cytokines as well as by growth 
factors and hormones (Bromberg, 2001; Schindler, 2002). Receptor-ligand coupling leads 
to conformational change of the receptor-associated tyrosine kinase known as Janus 
kinases (JAKs) recruiting STATs to the intracellular domain of the receptor. Subsequent 
phosphorylation of STATs leads to STAT homo- and heterodimerisation (pSTAT). 
STAT dimers rapidly translocate to the nucleus where they can bind to the DNA binding 
motifs (Aaronson and Horvath, 2002; Lim and Cao, 2006).  
Several studies showed an LPS induced activation of STAT1 and STAT3 in the Arc, 
suggesting an involvement of these pathways in iNOS expression under inflammatory 
condition. In fact, LPS triggers a time-dependent nuclear STAT3 translocation in the Arc 
and other brain areas in guinea pigs (Rummel et al., 2005) and rats (Gautron et al., 2002; 
Rummel et al., 2005). The LPS-induced nuclear translocation of STAT3 peaked after 4 
hours in the hypothalamus (Gautron et al., 2002). Moreover, a time dependent STAT3 
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phosphorylation occurs in the Arc of rats after LPS treatment 4 hours after injection 
(Riediger et al., 2010).  
Similar to what has been demonstrated for pSTAT3, peripheral LPS treatment induces 
pSTAT1 formation in the Arc of mice (Borner et al., 2012). In astroglial cell cultures 
JAK2/STAT1 is involved in iNOS expression (Dell'Albani et al., 2001). Furthermore, 
IFN-γ, IFN-γ receptor and STAT1 knockout mice are defective for the induction of NO 
synthesis by LPS and/or cytokines (Dalton et al., 1993; Kamijo et al., 1993; Meraz et al., 
1996). In mouse macrophages LPS triggers iNOS expression through JAK2/STAT1 
signaling (Tsoyi et al., 2008). Inhibition of JAK2/STAT-signaling by AG490, a JAK2 
inhibitor, reduced sickness behavior such as reduced locomotor activity and decreased 
water intake in LPS treated rats. These findings suggest a role of the JAK/STAT 
signaling in LPS induced sickness behavior (Damm et al., 2013). 
Together, these data suggest an involvement of JAK/STAT signaling the Arc after 
immune challenge with LPS. However, its specific involvement in LPS/NO-dependent 
effects on neuronal function in the Arc has not yet been investigated. 
 
3.6 Therapeutic approaches in disease related anorexia and ACS 
The management of chronic sickness anorexia and ACS represents a great challenge. No 
therapy has proven to be sufficiently effective in the treatment of the metabolic 
derangement caused by the ACS. The successful management of this accompanying 
catabolic disorder would further increase the therapy success and ameliorate the quality 
of life of the patients during their treatment. In the past two decades different therapeutic 
approaches and substances have been tested, e.g. anti-inflammatory agents, 
corticosteroids, progestagens. The exact mechanism of action of these compounds in 
treatment of anorexia is largely unknown. Moreover, most of them show severe side 
effects (Kumar et al., 2010). 
Among other treatment strategies, agonists of the growth hormone secretagogue receptor 
(GHS-R), like ghrelin and its mimetics, appear promising for the treatment of illness-
associated anorexia.  
Several studies with different anorexia and/or cachexia animal models evaluated the 
effectiveness of ghrelin treatment. In most of these studies ghrelin or ghrelin agonists 
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showed beneficial effect on food intake, body weight and body composition (DeBoer et 
al., 2007; Hanada et al., 2003; Hataya et al., 2003; Wang et al., 2006). 
However, there is some evidence for a decreased responsiveness to ghrelin treatment 
under tumor conditions. In fact, central ghrelin administration in tumor-bearing animals 
failed to increase food intake if compared to non-tumor-bearing controls and increased 
endogenous serum ghrelin levels accompanied this reduced effectiveness (Wisse et al., 
2001). These findings might suggest a state of ghrelin resistance or at least reduced 
ghrelin responsiveness under tumor conditions. 
Ghrelin or GHS-R agonists have been studied in few human studies. Most of them 
included cancer patients. (Burney B, 2012; Garcia and Polvino, 2007; Levinson and 
Gertner, 2012; Lundholm et al., 2010; Nagaya et al., 2005; Nass et al., 2008; Neary et al., 
2004; Strasser et al., 2008). Some of these studies indicate positive effects of treatment 
with ghrelin or its agonists on energy intake and body weight of the patients. Others did 
not report any beneficial effects of ghrelin treatment. However, due to the heterogeneity 
of the study design, negative findings should be interpreted with caution. 
Due to the short half-life of ghrelin (Akamizu et al., 2004) its therapeutic use in human is 
limited because of these the insufficient pharmacokinetic properties of the native 
peptidergic hormone. Synthetic ghrelin mimetics have longer half-life allowing a daily 
single administration (Blum R, 2006; Nass et al., 2008) and oral route of administration.  
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4 Questions 
1. Are JAK2/STAT- and NF-κB-signaling involved in the LPS-induced iNOS/NO-
mediated inhibition of orexigenic Arc neurons? 
Using electrophysiological single cell recording techniques we tested whether STAT and 
NF-κB pathway blockers inhibit LPS/NO-mediated inhibition of electrical activity of Arc 
neurons under in vitro conditions. If our assumptions were correct, we would expect a 
decreased number of ARC neurons showing disinhibitory responses to iNOS blockade 
after LPS stimulation (Figure 1). To inhibit the JAK2/STAT pathway, we used WP1066, 
which inhibits JAK2 activation preventing STAT1 and STAT3 phosphorylation (Ferrajoli 
et al., 2007; Heimberger and Priebe, 2008; Horiguchi et al., 2010). To inhibit NF-κB 
activation we used the compound Bay 11-7085, which inhibits IκB phosphorylation 
preventing an activation and nuclear translocation of NF-κB (Koedel et al., 2000; Pierce 
et al., 1997).  
 
 
Figure 1: Experimental approach for the electrophysiological studies. Co-incubation of Arc slice 
preparations in LPS with the NF-κB or JAK2/STAT inhibitor should prevent the disinhibition caused by 
the iNOS inhibitor 1400W. 
 
2. Is LPS sufficient to activate the STAT1 and STAT3 pathways in the Arc after in 
vitro stimulation? 
Since LPS-induced systemic inflammation in rats induces an activation of the STAT1 and 
STAT 3 pathway in the Arc, we wanted to study if a similar response occurs under in 
vitro conditions independently of a systemic immune response. For this purpose we used 
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immunohistochemical methods to examine if a pSTAT1 and pSTAT3 formation occurs 
after in vitro LPS stimulation of Arc slices as well.  
 
3. Does LPS treatment induce NF-κB-signaling in the Arc and the AP and which cell 
type is affected? 
We performed an immunohistological detection of NF-κB signaling in the Arc after LPS 
treatment in vivo as well as in vitro LPS stimulation. We further immunohistologically 
investigated whether NF-κB is activated in the AP after LPS treatment. 
 
4. Does HM01 mimic the effects of ghrelin on neuronal activity of Arc neurons? 
Using extracellular electrophysiological recordings we characterized the effect of the 
novel ghrelin analog HM01 (Helsinn Healthcare SA, Pambio-Noranco, Switzerland) on 
Arc neurons. As a specific ghrelin receptor agonist, HM01 is expected to mimic ghrelin-
induced responses as reflected by a high degree of co-sensitivity of Arc neurons to HM01 
and ghrelin.   
 
5. Does chronic administration of HM01 increase food intake and body weight in 
healthy rats? 
In these experiments the effect of chronic HM01 administration (subcutaneously 
implanted osmotic minipumps) on food intake and body weight development was 
investigated. According to ghrelin’s positive effects on energy balance, HM01 was 
expected to increase food intake and body weight gain. 
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5 Material und Methods 
5.1 Preface 
Most of the basic techniques used in the studies of this project were the same as reported 
in the master thesis “Intracellular pathways mediating nitric oxide dependent inhibition 
of orexigenic hypothalamic neurons by anorectic lipopolysaccharide” (Loi, 2012). 
Extensions or modifications were added for all additional experimental procedures of the 
current work. 
5.2 Animals and housing conditions 
For all experiments adult male Wistar rats (Elevage Janvier, Le-Genest-St. Isle, France) 
weighing between 200-380 g were used. Animals were kept in a temperature-controlled 
room (21 ± 1°C) on a 12:12 h light/dark cycle with ad libitum access to feed (standard 
chow, 890 25 W16, Provimi Kliba, Switzerland) and tap water. For the 
electrophysiological and immunohistochemical studies they were housed in groups of 
five animals in standard macrolon cages. For the in vivo testing of the ghrelin agonist 
HM01 10 animals were single housed in hanging wire-mash cages. Before the 
experiments, rats were handled daily and kept in the cages for an adaptation period of at 
least one week. All the experiments were conducted in accordance with the regulations of 
the Veterinary Office of the Canton Zurich, Switzerland. 
5.3 Preparation of the arcuate nucleus (Arc) for electrophysiological 
and in vitro immunohistological studies 
Artificial cerebrospinal fluid (aCSF) 
aCSF was used for the preparation and incubation of the brain slices as well as for the 
perfusion of the recording chamber during the electrophysiological recordings. Table 1 
shows the composition of the stock solutions and the final concentration of all the 
components. The stock solutions were stored at 4°C and the aCSF was prepared daily for 
each experiment in order to prevent bacterial growth. The final solution was oxygenated 
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and equilibrated with oxycarbon (95% O2, 5% CO2) for at least one hour before and 
during the entire duration of the experiments. 
Table 1 Composition of stock solution and final aCSF concentration 
Solution Substance Concentration (g/L) 
aCSF final 
concentration (mM) 
I 
NaCl 
KCl 
NaH2PO4.H2O 
MgSO4.7H2O 
72.46 
3.73 
1.65 
3.2 
124 
5 
1.2 
1.3 
II NaHCO3 21.84 26 
III CaCl2.2H2O 1.76 1.2 
IV Glucose H2O 19.82 10 
 
Preparation of arcuate nucleus slices  
The animals were decapitated using a guillotine. The skull was opened from the caudal 
side using a surgical rongeur and superfused with ice-cold aCSF. The olfactory bulb and 
the optic nerves were cut and the brain was transferred into a preparation dish containing 
ice-cold aCSF. The brainstem and the cerebellum were dissected with a cut at the level 
between cerebrum and cerebellum. The meninges were removed from the cerebrum using 
curved tweezers under a dissecting microscope. To prepare the arcuate nucleus the 
cerebrum was fixed with instant glue in vertical position and stabilized with an agar block 
in a vibratom chamber filled with ice-cold aCSF. A custom made vibratom (Leica VT 
1000S, Leica microsystems) was used to obtain 700 µm thick coronal brain slices 
containing the Arc, starting with the first section caudal to the end of the optic chiasm. 
The obtained slices where then manually trimmed to 3x3 mm sections containing the Arc 
(Figure 2) and finally transferred in the temperature controlled (37°C) incubation 
chamber containing 240 ml of continuously oxygenated aCSF.  
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Figure 2: Schematic half-section of the hypothalamus region close to the Arc. The grey area indicates the 
surface that has been removed and prepared for the following experiments. ArcM: medial arcuate nucleus, 
ArcL: lateral arcuate nucleus, ME: median eminence, 3V: third ventricle, sox: supraoptic decussation, mfb: 
medial forebrain bundle, opt: optic tract, f: fornix (modified from Paxinos and Watson, 1998). 
5.4 Electrophysiological studies 
5.4.1 Electrophysiological setup 
Recording chamber 
The recording chamber consisted of solid brass and was gold-plated. When perfused it 
contained a volume of 0.7 ml aCSF, which was constantly replaced at a rate of 1.6 
ml/min by a peristaltic pump (Minipuls 2, Gilson, ABIMED, Germany). The slice 
preparations were transferred to the recording chamber and fixed on the bottom with a 
small metal weight. 
 
Temperature control 
A thermocouple in the recording chamber transmitted the effective temperature of the 
aCSF to a Peltier-controller (PTC-10, npi electronics, Germany). A Peltier element fixed 
with heat conducting paste under the recording chamber kept the temperature of the aCSF 
at 37 ± 0.2°C. The superfused aCSF was prewarmed before entering the chamber. The 
monitored temperature signals were stored on a PC through an analog-digital converter 
(CED1410, Science Park, England). The temperature was checked and if necessary 
adjusted before the recordings. 
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Electrodes 
Extracellular recordings of single cell action potentials were obtained from Arc neurons 
using self-made glass-coated platinum-iridium electrodes. After sharpening the electrodes 
(platinum/iridium 70/30, 0.1 mm diameter, Chempur, Germany) electrolytically in a 
NaCN-solution (30% NaCN, 30% NaOH) up to a tip diameter of about 2 µm, they were 
glass coated with a vitrification device for electrical isolation. To allow electrical 
conductance the glass was removed from the tip of the electrode by melting. The 
electrodes were connected to a 3-axis hydraulic micromanipulator (MHW-103, Narishige, 
Japan). The electrode was carefully inserted into the tissue under optical guidance until 
an action potential was detected. According to the neuroanatomical brain map of Paxinos 
and Watson (Paxinos and Watson, 2007) the recordings were conducted in the medial 
Arc, where NPY neurons are located that are activated by the orexigenic hormone ghrelin. 
 
Signal processing 
The extracellularly recorded action potentials were first amplified 1000-fold by a 
differential amplifier (DAM50, WPI, USA) and after passing a high- and low-pass filters 
they were amplified 10-fold and recorded by a DAT-recorder (DTR-1205, Bio-Logic, 
Science Instruments, France). A window discriminator (SL-04, BM&T, Heidelberg, 
Germany) allowed a discrimination of action potential signals from background noise. 
When the voltage of the action potential passed an adjustable threshold level the window 
discriminator generated a TTL-signal (Transitor-Transitor-Logic). At the same time, the 
signals were passed to an analogue oscilloscope (COS5020, Kikusui electronics, Japan) 
and to a digital storage oscilloscope (DRO1602, Gould, UK), which was externally 
triggered by the TTL signals generated by the windows discriminator. The TTL-signals 
were converted by a CED 1401 interface (Cambridge Electronic Design UK) and 
recorded as ratemeter histograms with an interval of 5 seconds. An audiomonitor (AM8, 
Grass Medical Instruments, Quincy Massachusetts) facilitated the search for active cells 
(Figure 3). 
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Figure 3: Electrophysiological setup stand (from T. Riediger) 
5.4.2 In vitro stimulation 
In order to test whether the activation of NF-κB and JAK2-dependent STAT 
phosphorylation are involved in the LPS induced iNOS-dependent NO formation, Arc 
slices were incubated for 4 hours with LPS (100 ng/ml) in combination with Bay 11-7085 
(10-6 M) or WP 1066 (10-5 M). Bay 11-7085 and WP 1066 were dissolved in DMSO and 
stored in frozen aliquots. LPS was freshly prepared before each experiment. To control 
for the vehicle used for Bay 11-7085 and WP1066 250 µl of DMSO were added to the 
aCSF (Table 2). 
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Table 2: Substances used for the incubation and their molecular weight (MW), stock solution, final 
concentration and source of supply. 
5.4.3 Substance application 
For the superfusion of the tested substances a three-way valve was connected to the 
superfusion tubing system. The substances were added to a 10 ml syringe filled with 
aCSF and due to the small diameter of the tubing system they reached the recording 
chamber 60 s after the onset of the stimulus. Ghrelin, 1400W, Bay 11-7085, WP 1066, 
GLP-1 and HM01 were stored in frozen aliquots at -20°C. SNP was prepared before each 
experiment. The final concentrations are shown in (Table 3). Bay 11-7085 and WP1066 
were superfused to test whether the compounds have short-term effects on neuronal 
activity of the recorded neurons. To test NO responsiveness SNP was superfused; further, 
ghrelin was used as functional reference stimulus. The ghrelin-agonist HM01 was 
superfused after ghrelin stimulation to look for co-sensitivity of the neurons for these two 
substances. When a recording of a single cell action potential was established, the 
neuronal activity was recorded for at least 600 s. If a stable baseline was observed during 
this period of time, the stimulus was set. At the beginning and the end of the stimuli a 
marker was set in the continuous ratemeter recordings via keyboard inputs. For data 
analysis, a duration of 60 s was taken into account to correct for the lag time caused by 
the substance passage through the tubing system. 
 
Substance 
MW 
(g/mol) 
Stock solution 
Final 
concentration 
Source of supply 
LPS 
E.coli, serotype 
0111:B4 
- Daily prepared; 4°C 100 ng/ml Sigma-Aldrich 
Bay 11-7085 249.3 
2.4 . 10-3 M 
(in 250 µl DMSO) 
10-6 M Sigma-Aldrich 
WP 1066 356.22 
2.4 . 10-2 M 
(in 250 µl DMSO) 
10-5 M Calbiochem 
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Table 3: Substances used for the superfusion and their molecular weight (MW), stock solution, final 
concentration and source of supply 
Substance 
MW 
(g/mol) 
Stock solution 
Final 
concentration 
Source of 
supply 
Bay 11-7085 249.3 2 . 10-4 M in DMSO aliquot 10-6 M Sigma-Aldrich 
WP 1066 356.22 2 . 10-3 M in DMSO aliquot 10-5 M Calbiochem 
1400 W 250.2 10-2 M in H2O aliquot 10-4 M Calbiochem 
SNP 298 
0,4-1 mg aliquote; room 
temperature; freshly 
prepared 
10-5 M Calbiochem 
Ghrelin 
(rat recombinant) 
3315 10-5 M in H2O aliquot; 10-8 M Bachem 
HM01 437.86 10-3 M in H2O aliquot; 10-6/10-7 M Helsinn 
GLP-1 
(7-36) amide  
3297.68 10-4 M in H2O aliquot 10-7 Bachem 
5.4.4 Data evaluation and statistics 
The program Spike2 (CED, England) was used to record the firing rate, the temperature 
and the keyboard markers. The obtained histogram showed the recorded impulses in an 
interval of 5 seconds. The average discharge rate of the neuron was determined for 60 
seconds preceding the stimulus. This “mean spontaneous activity” was subtracted from 
the changes in firing rate resulting in the absolute mean response (Hz) that was then used 
to calculate the percentage of change in firing rate (%). Additionally the following 
parameters were evaluated: the latency (period of time between the begin of the stimulus 
in the chamber and the onset of the response), the duration (period of time between the 
beginning and the end of the response), the absolute (Hz) and relative (%) peak response 
(30 s interval of the maximum or minimum firing rate during the response). A neuron 
was considered sensitive to the applied substance if the averaged change of firing rate 
during the response was larger than ± 20% and ± 0.5 Hz. The parameters were averaged 
and expressed as mean ± standard error. The percentage of disinhibited neurons after 
1400W superfusion was compared between the LPS incubation and the co-incubation 
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with LPS and the inhibitors using the Fisher’s exact test. The effect parameters were 
analyzed using the Student’s t-test, one-way ANOVA or the Kruskal-Wallis Test if not 
normally distributed. The Newmann-Keuls Multiple Comparison Test served as post hoc 
test. 
5.5 Immunohistological studies 
5.5.1 In vitro LPS stimulation 
Rats were decapitated and 700 µm thick coronal brain slices containing the Arc were 
prepared as described before and transferred to the incubation chamber. The Arc slices of 
one half of the animals were stimulated with LPS (100 ng/ml) for 1 or 4 h. The slices of 
the remaining animals served as control and were kept 1, or 4h in aCSF. The obtained 
sections were processed for pSTAT or NF-κB immunostaining. 
5.5.1.1 STAT phosphorylation 
Fixation and slicing 
After the incubation the Arc preparations were transferred to a 12 well-plate filled with 2 
ml of oxygenated aCSF. 2 ml of ice-cold 4% Fix were added in each well (final conc. 2% 
Fix) and the plates were stored at 4° C for 1 h. The fixative was replaced with 2 ml of 
20% sucrose in 0.02 M KPBS (potassium phosphate buffered saline, Table 5) for 3 h at 
4°C. The slices were mounted on parafilm covered glass slides and residual sucrose was 
removed with filter paper. The preparations were covered with tissue freezing medium 
(Leica Microsystems, Nussloch, Germany) and frozen at -20°C in a cryostat (Leica 
CM3050S, Nussloch, Germany). Two series of 20 µm thick sections were obtained using 
the cryostat and mounted on adhesive glass slides (Menzel-Gläser, Superfrost® Plus, 
Thermo scientific, Braunschweig, Germany). The sections were processed for pSTAT1 
and pSTAT3 immunoreactivity. 
 
Staining 
The slices were air dried for 1 hour and rehydrated in 0.02 M KPBS (Table 5). Antigen 
retrieval was achieved by 20 min incubation at room temperature in 0.02 M KPBS 0.3% 
NaOH and 0.3% H2O2. Sections were incubated first in 0.02 M KPBS 0.3% glycine for 
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10 min followed by 10 min incubation in 0.02 M KPBS 0.03% sodium dodecyl sulfate 
(SDS). Unspecific binding was blocked by incubation in 4% donkey normal serum 
(DNS), 0.4% Triton® X-100, 1 bovine serum albumin (BSA) in KPBS at room 
temperature for 20 min. The two primary antibodies (rabbit anti-pSTAT1, 1:50, Santa 
Cruz Biotechnology and rabbit anti-pSTAT3, 1:500, Cell signaling Technology) were 
applied for 48h at 4° C in KPBS containing 1% DNS, 0.4% Triton® X-100, 1% BSA. The 
secondary antibody (donkey anti-rabbit Alexa 555, 1:100, Invitrogen) was applied in 
KPBS containing 1% DNS, 0.3% Triton® X-100 for 2h at room temperature. Finally the 
sections were coverslipped with citifluor (Citifluor Ltd, London). 
5.5.1.2 NF-κB activation  
After an incubation of 1 hour the Arc and AP preparations were processed like for the 
pSTAT staining. In this case, the final concentration of fixative was 4% and PBS (Table 
4) was used instead of KPBS.  
 
Staining 
The staining protocol was the same as used for the tissue of the in vivo LPS stimulation 
(see point 5.5.2).  
5.5.2 NF-κB activation after in vivo LPS stimulation 
LPS injection and perfusion 
Rats were randomly assigned to one of the experimental groups. At dark onset the 
animals were intraperitoneally (i.p.) injected either with LPS (from E. coli, serotype 
0111:B4, Sigma-Aldrich, Buchs, Switzerland) or with saline. LPS was dissolved in sterile 
0.9% NaCl and injected at doses of 100 or 300 µg/kg BW. The animals were deeply 
anesthetized 2 or 4 hours later by an i.p. injection of pentobarbital (80 mg/kg ip). The 
thorax was opened and the rats were transcardially perfused for 1.5 minutes with ice cold 
PB 0.1 M (phosphate buffer) pH 7.2 followed by ice cold paraformaldehyde solution (4% 
PFA in 0.1 M PB) for 2 minutes. The brains were postfixed in 4% PFA for 2 hours at 4°C 
and then transferred to 20% sucrose in PB for 2 days at 4°C for cryoprotection. Brains 
were snap-frozen at -20°C in hexane. 20 µm Arc and AP sections were cut using a 
cryomicrotome and mounted on adhesive glass slides.  
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Tissue processing and staining 
Sections were air dried for 1 hour and then rehydrated in PBS (Table 4). Unspecific 
binding was blocked by incubation in 5% DNS in PBST 0.3% (phosphate buffer saline, 
0.3 % Triton® X-100) for 1 hour at room temperature. The primary antibodies (Table 6, 
Table 7) were applied in 0.3% PBST for 3 days at 4°C. The secondary antibodies (Table 
6, Table 7) were applied in PBST 0.3% for 2 hours at room temperature. After washing in 
PBS, DAPI staining was performed. 300 nM DAPI (DAPI dihydrochloride, Life 
Technologies, NY, USA) in PBS was applied at room temperature for 5 minutes. After 
final washing the section were coverslipped with Citifluor. 
5.5.3 Evaluation and statistics of immunohistochemical studies 
A fluorescence microscope equipped with a digital camera system (AxioImager, Carl 
Zeiss AG) was used to analyze the slices.  
To quantify the number of pSTAT1 and pSTAT3 immunoreactive cells, five 
corresponding Arc sections from each animal were analyzed in blind fashion and the 
number of immunoreactive cells was averaged for each animal.  
To evaluate the activation of NF-κB the co-localization of NF-κB and DAPI fluorescence 
was analyzed. Five corresponding Arc or AP sections from each animal were analyzed 
manually in blind fashion and the number of cells with nuclear NF-κB was averaged for 
each animal.  
From these averaged values the means ± SEM were determined for each group. Statistical 
evaluation between groups was performed using Student´s t-test or one-way ANOVA. 
Dunn’s Multiple Comparison Test served as post hoc test. 
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Table 4: PBS buffer 
Substance Weight (g)  
NaCl 8  
KCl 0.2 Dissolved in 1 l of dd H2O 
Na2HPO4 1.8  
KH2PO4 0.2  
Table 5: KPBS buffer 
Substance Weight (g)  
KH2PO4 9.7 Dissolved in 20.58 l dd 
K2HPO4 56.6 H2O to final concentration 
NaCl 178.2 of 0.02 M 
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Table 6: Antibodies used for NF-κB immunostainings in the arcuate nucleus 
Primary antibody Secondary antibody 
Antibody Supplier Concentration Antibody Supplier Concentration 
Rabbit anti- 
NF-κB 
p65 subunit  
(C 20) 
sc-372, 
Santa Cruz 
Bio-
technology 
Inc, 
1:500 
Donkey anti-
rabbit Alexa-
555 
Invitrogen, 
Life 
Technologies,  
1:100 
Sheep anti-
rat von 
Willebrand 
Factor 
SARTW-IG 
Stago BNL, 
 
1:3’000 
Dpnkey anti-
sheep 
Alexa-488 
Invitrogen, 
Life 
Technologies,  
1.200 
Table 7: Antibodies used for NF-κB immunostainings in the area postrema 
Primary antibody Secondary antibody 
Antibody Supplier Concentration Antibody Supplier Concentration 
Rabbit anti-
NF-κB 
p65 subunit 
(C 20) 
sc-372, 
Santa Cruz 
Biotechnology 
Inc, 
1:500 
Donkey anti-
rabbit Alexa-
555 
Invitrogen, 
Life 
Technologies,  
1:300 
Mouse anti-
RECA-1 
MCA970R 
AbD Serotec,  
1:2’000 
Donkey anti-
mouse 
Alexa-488 
Invitrogen, 
Life 
Technologies,  
1:200 
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5.6 Implantation of the osmotic minipumps 
After an adaptation period of one week 10 animals were randomly assigned to one of the 
two experimental groups (n = 5). An osmotic minipump (ALZET® osmotic pumps, 
DURECT corporation, Cupertino, CA 95015-0530) was implanted subcutaneously in one 
flank at the lower level of the abdomen between the chest and the hind limbs. Half of the 
minipumps were filled with saline (controls), whereas the remaining minipumps were 
filled with HM01 (10 µg/µl). The total volume of the minipumps was 2 ml. One hour 
prior to anesthesia the animals were treated with Norocarp® (10 mg/kg s.c., ufamed AG, 
Sursee, Switzerland). Anesthesia was induced in a Plexiglas chamber with 5% isoflurane 
in oxygen (1 l/min). After an adequate depth of anesthesia was achieved, rats were 
sheared with an electric razor and disinfected with betadine scrub. Rats were then placed 
in prone position on a heating pad and the head was positioned in a nose cone. For the 
maintenance of anesthesia 2–4% isoflurane in oxygen, was supplied for the duration of 
surgery. A 2 cm skin incision was made in the caudal part of the lateral torso. The 
subcutaneous tissue was spread by opening and closing the jaws of a Metzenbaum scissor. 
This procedure created a pocket for the minipump. The filled minipumps were inserted 
into the pocket and the incision was closed with an intracutaneous suture. The pumps 
delivered the compound into the subcutaneous space. The minipump released a constant 
amount of HM01 (50 µg/h with a pump rate of 5 µl/h). The capacity of the minipump 
allowed a constant compound release of 14 days. Body weight and food intake were 
measured daily. Thirteen days after minipump implantation the animals were deeply 
anesthetized and transcardially perfused as described before. All data are expressed as 
mean ± SEM. Food intake and body weight were compared at each time point using a 
parametric unpaired student’s t-test. 
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6 Results 
6.1 Intracellular pathways involved in the iNOS mediated NO 
production in the Arc 
During this first part of the electrophysiological studies 48 ArcM neurons were recorded. 
The mean amplitude of the action potentials was 120 µV, which allowed an accurate 
discrimination from background noises. 
 
1400W sensitivity after incubation with LPS (100 ng/ml) 
 
After 4 h incubation with LPS 8 neurons were superfused with 1400W and their electrical 
activity was recorded and analyzed. 63% of the recorded neurons (5/8) showed an 
increase in their firing rate in response to 1400W (Figure 4), while the remaining neurons 
were 1400W-insensitive. SNP sensitivity was tested in 5 recordings, 4 (80%) of the cells 
were reversibly inhibited, while one neuron was insensitive. 80% (4/5) of the neurons 
that were tested for ghrelin sensitivity showed an excitatory response while 1 neuron was 
insensitive. 
 
 
Figure 4: Representative recording of ArcM neuron, which increased the firing rate after 1400W 
superfusion (10-4 M) after 4 h incubation with LPS (100 ng/ml). The neuron was inhibited by SNP (10-5 M). 
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The excitatory responses to 1400W started after a mean latency of 700 ± 149 s and 
displayed a mean response duration of 762 ± 136 s. During the stimulatory response, the 
mean absolute increase of the firing rate was 1.5 ± 0.5 Hz with a mean spontaneous 
activity of 0.9 ± 0.6 Hz before the superfusion of 1400W (Table 8). 
 
Table 8: Effect parameters of the excitatory responses induced by 1400W (10-4M) after LPS in vitro 
stimulation (n = 5). 
Parameters M ± SEM 
Mean spontaneous activity (Hz) 0.9 ± 0.6 
Mean latency (s) 700 ± 149 
Absolute response (Hz) 1.5 ± 0.5 
Absolute peak response (Hz) 2.4 ± 0.8 
Mean response duration (s) 762 ± 136 
To test the co-sensitivity for 1400W and ghrelin we compared the response of the 
recorded neurons (n = 5) to both substances. 60% (3/5) of the tested neurons showed an 
excitatory response to both substances (Table 9). 
Table 9: Co-sensitivity between 1400W (10-4 M) and ghrelin (10-8 M) tested after in vitro LPS stimulation 
(n = 5). 
  1400 W    
  Excited Inhibited Insensitive Total 
Ghrelin Excited 3 (60%) 0 (0%) 1 (20%) 4 (80%) 
 Inhibited 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
 Insensitive 1 (20%) 0 (0%) 0 (0%) 1 (20%) 
 Total 4 (80%) 0 (0%) 1 (20%)  
 
Involvement of NF-κB signaling in the iNOS mediated NO production in the Arc 
 
To test possible immediate effects on neuronal activity of the compound Bay 11-7085, 10 
Arc neurons were superfused with Bay 11-7085. None of the neurons showed a 
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significant response to the NF-κB inhibitor. Figure 5 shows a SNP-inhibited/ghrelin-
excited Arc neuron that was insensitive to Bay 11-7085. 
 
Figure 5: Representative recording of an ArcM neuron showing that superfusion of Bay 11-7085 (10-6 M) 
did not alter neuronal activity. This neuron was inhibited by SNP (10-5 M) and excited by ghrelin (10-8 M). 
To test the involvement of NF-κB in LPS-mediated iNOS-dependent NO signaling in the 
Arc, we incubated Arc slices with LPS and the NF-κB inhibitor Bay 11-7085. After the 
incubation the sensitivity of ArcM neurons for 1400W was tested. 90% (9/10) of the 
tested neurons were 1400W-insensitive (Figure 6). Only one neuron (10%) showed a 
significant increase in the baseline activity after 1400W superfusion (Figure 7). 50% of 
the neurons were insensitive to ghrelin administration, 30% (3/10) were excited and 20% 
(2/10) showed a decrease in their baseline activity. SNP was tested on 9 neurons and it 
reversibly inhibited 8 of them (89%), while 1 neuron was insensitive (11%). 
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Figure 6: Recording of a representative ArcM neuron insensitive to 1400W (10-4 M), SNP (10-5 M) 
inhibited and ghrelin (10-8 M) excited after 4 h incubation with LPS (100 ng/ml) and Bay 11-7085(10-6 M). 
 
Figure 7: Recording of the only ArcM neuron that showed an increase in baseline activity after 1400W 
administration after 4 h incubation with LPS (100 ng/ml) and Bay 11-7085 (10-6 M). The cell was inhibited 
by the NO donor SNP (10-5 M) but was insensitive to ghrelin (10-8 M). 
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Involvement of STAT signaling in the iNOS mediated NO production in the Arc 
 
To investigate a possible short-term effect on the electrical activity of the Arc neurons, 
we tested the compound WP1066 on 10 neurons. 6 neurons (60%) did not show any 
change in their baseline activity (Figure 8). 40 % of the recorded neurons were affected 
by WP1066 superfusion: 2 (20%) of them where inhibited (Figure 9), while other 2 
neurons showed an increase in their firing rate (Figure 10). 
 
Figure 8: Representative recording of an ArcM neuron without change in the baseline activity after 
superfusion with WP1066 (10-5 M). 
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Figure 9: Representative recording of an ArcM neuron, which was inhibited after superfusion of WP1066  
(10-5 M). 
 
 
Figure 10: Representative recording of an ArcM neuron, which was excited after superfusion of WP1066 
(10-5 M) and excited by ghrelin (10-8 M). 
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In order to investigate the involvement of STAT signaling in the LPS triggered iNOS-
dependent NO production, the Arc sections were incubated in LPS and the JAK2/STAT 
inhibitor WP1066. 67% (8/12) of the recorded neurons were 1400W insensitive (Figure 
11). 25% (3/12) of the neurons showed a significant increase in their firing rate after 
1400W superfusion (Figure 12), while 1 neuron (8%) showed a decrease in the firing rate. 
100% of the neurons tested for SNP sensitivity (9/9) showed a strong and reversible 
inhibition. Ghrelin lead to excitatory effect in 33 % (4/12) of the recorded neurons. 58% 
(7/12) were insensitive and 1 neuron (8%) showed a decrease in the firing rate. 
 
Figure 11: Recording of an ArcM neuron after co-incubation with LPS and WP1066 (10-5 M) insensitive to 
1400W (10-4 M), inhibited by SNP (10-5 M) and insensitive to ghrelin (10-8 M). 
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Figure 12: Representative ArcM neuron after 4 h incubation with LPS (100 ng/ml) and WP1066 (10-5M), 
which showed an increase in baseline activity after 1400W (10-4 M) administration. The neuron was 
inhibited by SNP (10-5 M) and excited by ghrelin (10-8 M). 
 
The excitatory effect of 1400W started with a mean latency of 376 ± 70 s after the 
substance reached the recording chamber and displayed a mean response duration of 
1436 ± 58 s. During the stimulatory response, the mean absolute increase of the firing 
rate was 0.8 ± 0.2 Hz with a mean spontaneous activity of 2.7 ± 1.1 Hz before the 
superfusion of 1400W (Table 10). 
Table 10: Effect parameters of the excitatory responses induced by 1400W (10-4 M) after incubation with 
LPS (100 ng/ml) and WP1066 (10-5 M) (n = 3). 
Parameters M ± SEM 
Mean spontaneous activity (Hz) 2.7 ± 1.1 
Mean latency (s) 376 ± 70 
Absolute response (Hz) 0.8 ± 0.2 
Absolute peak response (Hz) 1.4 ± 0.3 
Mean response duration (s) 1436 ± 58 
  
 Page 43 
Percentage of 1400W sensitive cells 
 
Figure 13 shows the percentage of 1400W sensitive cells after incubation with LPS and 
co-incubation with LPS and Bay 11-7085 or WP1066. After LPS incubation 63% of the 
recorded neurons showed an increase in their firing rate after 1400W superfusion. After 
co-incubation with LPS and Bay 11-7085 only 10% of the tested neurons were 1400W 
sensitive. After co-incubation with LPS and WP1066 25% of the neurons were exited 
after 1400W application and 8% showed an inhibition. Using the Fisher’s exact test we 
found a significant difference in proportion of 1400W sensitive cells between the LPS 
incubated group and the LPS/Bay 11-7085 co-incubated group (p = 0.043). On the other 
hand no significant difference was found between the LPS incubated group and the 
LPS/WP1066 co-incubated group (p = 0.18). 
 
 
Figure 13: Percentage of 1400W sensitive cells. (Analysis conducted using the Fischer’s exact test; * = p < 
0.05; n.s. = p > 0.05) 
  
 Page 44 
6.2 NF-κB activation after in vivo LPS stimulation 
The aim of these experiments was to investigate whether nuclear translocation of NF-κB 
occurs after in vivo LPS stimulation. We analyzed nuclear translocation of NF-κB at 2 
and 4 hours after LPS injection. 
6.2.1 NF-κB activation 4 hours after LPS injection 
The animals were randomly assigned to one of the two groups. Half of the animals were 
injected intraperitoneally with 100 µg/kg LPS. The rest of the animals served as saline-
treated controls. Activation of the NF-κB pathway was detected by a doublestaining for 
NF-κB and DAPI, which binds to dsDNA resulting in a nuclear staining. 
4 h after LPS injection NF-κB immunoreactivity in the Arc was present in both groups 
(Figure 14). The Arc displayed a high immunoreactivity in blood vessels (Figure 15 and 
Figure 16) and NF-κB-positive cells were present in the brain parenchyma. At this time 
point immunoreactivity was confined to the cytoplasm indicating the absence of nuclear 
translocation of NF-κB in both treatment groups (Figure 17 and Figure 18). Similarly 
there was no obvious difference in the density or intensity of NF-κB immunoreactivity 
between the LPS and the saline treated group (Figure 14). 
 
Figure 14: NF-κB immunostaining of the Arc 4 hours after saline or LPS injection. (3rdV = third ventricle, 
scale bar = 100 µm) 
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Figure 15: NF-κB immunostaining in the Arc 4 hours after LPS injection showing an immunoreactive 
blood vessel (arrow). (Scale bar 50 µm) 
 
Figure 16: NF-κB immunostaining of the Arc after saline treatment showing c NF-κB immunoreactivity in 
a blood vessel (arrow). (Scale bar = 50 µm) 
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Figure 17: NF-κB immunostaining in the Arc 4 hours after LPS injection (Scale bar = 50 µm). 
 
Figure 18: NF-κB/DAPI double-staining (red and blue, respectively) in the Arc of an LPS-treated rat 
showing cytoplasmatic localization of NF-κB immunoreactivity (arrows). The blue staining represents 
DAPI positive cell nuclei. (Scale bar = 50 µm) 
6.2.2 NF-κB activation 2 hours after LPS stimulation 
Proceeding from the negative outcome of the study conducted at the 4h time point, we 
analyzed the effect of LPS on NF-κB activation 2h after treatment at the standard dose of 
100 µg/kg and a higher dose of 300 µg/kg LPS (hLPS). The area postrema was included 
in these studies. The NF-κB/DAPI staining was combined with the immohistochemical 
detection of the vascular markers von Willebrand factor or RECA-1. The latter staining 
 Page 47 
was used for the AP because we did not detected vW immunoreactivity in the AP (data 
not shown).    
 
Arcuate nucleus 
 
NF-κB immunoreactivity in the Arc was seen in each of the treatment groups (Figure 20) 
without obvious differences. Although the highest numbers of NF-κB/DAPI positive cells 
were detected in animals belonging to the LPS treatment groups, the absolute cell counts 
were very low and characterized by considerable individual variability. For these reasons, 
we were unable to detect a significant effect of LPS treatment on nuclear translocation of 
NF-κB as measured by the co-localization of NF-κB immunoreactivity and DAPI 
fluorescence (Figure 19).   
All cells showing a NF-κB/DAPI co-localization were identified as endothelial cells, 
while in non-vascular cells of the brain paremchyma NF-κB immunoreactivity was 
confined to the cytoplasm (Figure 21). 
 
 
Figure 19: Numbers of cells with nuclear localization of NF-κB 2 hours after injection of LPS (one-way 
ANOVA, p > 0.05). (LPS  = 100 µg/kg, hLPS = 300 µg/kg). 
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Figure 20: NF-κB immunostaining in the Arc 2 hours after injection with saline, LPS (100 µg/kg) and 
hLPS (300 µg/kg). (Scale bar = 100 µm) 
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Figure 21: Nuclear translocation (close arrows) of NF-kB in endothelial cells of the Arc 2 hours after LPS 
injection (100 µg/kg). Open arrow: endothelial cell without nuclear NF-κB staining. Arrowhead: non-
vascular cell in the brain parenchyma without nuclear translocation of NF-κB. (A) NF-κB (red), (B) NF-κB 
+ DAPI (blue), (C) NF-κB + vW (green), (D) vW (scale bar = 20 µm). 
 
Area postrema 
 
2 hours after injection of LPS NF-κB immunoreactivity was seen in the AP in all groups 
(Figure 23). Nuclear translocation of NF-κB was detected in some cells. To phenotype 
these cells an antibody against the rat endothelial cell antigen-1 (RECA-1) was used to 
mark endothelial cells of the AP. The cells that showed NF-κB activation were identified 
as endothelial cells or were in close vicinity to vascular structures (Figure 24 and Figure 
25). The sections of animals treated with LPS or hLPS showed a significantly increased 
number of cells with nuclear translocation of NF-κB (Figure 22). 
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Figure 22: Number of cells with nuclear staining of NF-κB. 2 hours after injection of LPS (Kruskal-Wallis 
test p = 0.0049; Dunn’s Multiple Comparison Test served as post hoc test). 
 
 
   
Figure 23: NF-κB immunoreactivity in the AP 2 h after injection. LPS = 100 µg/kg, hLPS = 300 µg/kg. 
(Scale bar = 100 µm).  
Saline 
LPS hLPS 
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Figure 24: Nuclear translocation of NF-kB in endothelial cells of the AP (arrow) 2 hours after LPS 
injection (100 µg/kg). (A) NF-κB, (B) NF-κB + DAPI, (C) NF-κB + RECA-1, (D) RECA-1.  
(scale bar = 20 µm). 
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Figure 25: Immunostaining of the AP 2 hours after LPS injection (300 µg/kg). Closed arrow: nuclear 
translocation of NF-kB in a cell in close vicinity to a blood vessel Open arrows: two endothelial cells 
without nuclear localization of NF-κB (A) NF-κB (red), (B) NF-κB + DAPI, (C) NF-κB + RECA-1 (green), 
(D) DAPI (blue). (Scale bar = 10 µm) 
6.3 NF-κB activation after in vitro stimulation of Arc sections 
To investigate whether in vitro incubation with LPS leads to activation of NF-κB, Arc 
sections were incubated for 1 h and a NF-κB triple staining with DAPI and vW was 
performed. After 1 h in vitro incubation, NF-κB immunoreactivity was seen in both 
groups. A high number of cells with nuclear staining of NF-κB was present in the LPS 
incubated sections, but also in the controls (Figure 27). There was no difference in the 
number of cells with nuclear NF-κB staining between the controls and the LPS stimulated 
sections (Figure 26). Most of these cells were located in a 100-200 µm wide margin at the 
outer area of the tissue slices (Figure 27).  
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Figure 26: NF-κB immunostaining in the Arc after 1 h incubation in aCSF (control) or LPS (100 ng/ml). 
No difference was seen between the two groups (Mann-withney test). 
 
 
 
Figure 27: NF-kB immunoreactivity in the Arc after 1 h in vitro incubation in aCSF (control) or LPS (100 
ng/ml). (3rdV = third ventricle, scale bar = 100 µm) 
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Figure 28: NF-κB immunoreactivity in the Arc after 1h incubation in aCSF (control). Close arrows: nuclear 
translocation of NF-κB in endothelial cells; open arrow: NF-κB translocation in non-vascular cells spread 
through the parenchyma (A) NF-κB (red), (B) NF-κB + DAPI (blue), (C) NF-κB + vW (green), (D) vW 
(scale bar = 20 µm). 
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6.4 STAT1 and STAT3 phosphorylation in the Arc after in vitro LPS 
stimulation 
It has been shown in previous studies that in vivo LPS treatment induces phosphorylation 
of both STAT1 and STAT3 in the Arc 4 h after injection. To investigate whether in vitro 
incubation with LPS triggers a phosphorylation of STAT1 and STAT3, Arc sections were 
incubated in LPS for 4 h and a staining for pSTAT1 and pSTAT3 was performed. 
In vitro incubation of Arc slices for 4 h in LPS triggered a STAT3 phosphorylation in the 
Arc of rats. LPS stimulated sections showed a significantly increased number of pSTAT3 
positive cells (Figure 29).  
No significant difference in STAT1 phosphorylation was noticed between the in vitro 
LPS stimulated group and the control group (Figure 30).  
 
 
Figure 29: pSTAT3 immunostaining in the Arc after 4 h incubation in aCSF (control) or LPS. (3rdV = third 
ventricle, scale bar = 50 µm). 4h LPS incubation lead to a significantly increased number of pSTAT3 
immunoreactive cells (Student’t test, p < 0.005) 
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Figure 30: pSTAT1 immunostaining of the Arc after 4 h incubation in aCSF (control) or LPS. (3rdV = third 
ventricle, scale bar = 50 µm). 4h LPS incubation did not lead to a significant difference in the number of 
pSTAT1 immunoreactive cells in the Arc (Student´s t-test). 
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6.5 Co-sensitivity of Arc neurons for HM01 and ghrelin 
In the second part of the electrophysiological studies 17 ArcM neurons were recorded. 
The mean amplitude of the action potentials was 185 µV, which allowed an accurate 
discrimination from background noises. 
To determine the co-sensitivity for ghrelin and HM01 we compared the responses of the 
recorded neurons (n = 17) to both substances (Table 11). 100% of the tested neurons 
showed the same response after ghrelin and HM01 superfusion (10-6 to10-7 M). 76% 
(13/17) were exited by both ghrelin and HM01, 1 neuron (6%) was inhibited and 18% 
(3/17) were insensitive to both substances. We tested the ghrelin-agonist HM01 at two 
different concentrations (10-6 and 10-7 M). 
Table 11: Co-sensitivity between ghrelin (10-8 M) and HM01 (10-6/10-7 M) (n=17). 
  HM01    
  Excited Inhibited Insensitive Total 
Ghrelin Excited 13 (76%) 0 (0%) 0 (0%) 13 (76%) 
 Inhibited 0 (0%) 1 (6%) 0 (0%) 1 (6%) 
 Insensitive 0 (0%) 0 (0%) 3 (18%) 3 (18%) 
 Total 13 (76%) 1 (6%) 3 (18%)  
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Excitatory responses after ghrelin and HM01 superfusion 
 
76% (13/17) of the recorded ArcM neurons showed an excitatory response after both 
ghrelin and HM01 (Figure 31 and Figure 32) 
 
Figure 31: Representative recording of an ArcM neuron, which shows an excitatory response after 
superfusion of ghrelin (10-8 M) and HM01 (10-6 M). 
 
Figure 32: Representative recording of an ArcM neuron, which was exited after superfusion of ghrelin (10-8 
M) as well as after HM01 (10-7 M). 
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We compared the effect parameters of the excitatory responses (Table 12) after 
superfusion of ghrelin (10-8 M), HM01 (10-6 M) and HM01 (10-7 M) using a one-way 
ANOVA or the Kruskal-Wallis test if not normally distributed. The excitatory responses 
after superfusion of HM01 (10-7 M) showed a significant longer latency period compared 
to the responses induced by ghrelin and HM01 (10-6 M) (p = 0.03). After superfusion of 
HM01 (10-6 M) the excitatory responses lasted significantly longer in comparison to 
ghrelin-induced stimulatory effects (p = 0.03). The spontaneous activity and the absolute 
responses did not differ between the three groups (Figure 33) 
Table 12: Effects parameters of the excitatory responses after superfusion of ghrelin 10-8 M (n=13), HM01 
10-6 M (n=8) and HM01 10-7 M (n=5) 
Parameters 
Ghrelin 10-8 M 
(M ± SEM) 
HM01 10-6 M 
(M ± SEM) 
HM01 10-7 M 
(M ± SEM) 
Mean spontaneous activity 
(Hz) 
2.7 ± 0.5 2.5 ± 0.7 1.7 ± 0.7 
Mean latency (s) 53± 7.9 63 ± 13.7 128 ± 36.3 
Absolute response (Hz) 2.5 ± 0.6 2.7 ± 0.6 3.9 ± 1.1 
Absolute peak response 
(Hz) 
5.2 ± 1 4.5 ± 1 6.1 ± 1.7 
Mean response duration 
(s) 
899 ± 76.2 2103 ± 552 1952 ± 537 
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Figure 33: Effect parameters of the excitatory responses induced by ghrelin (10-8 M) and HM01 (10-6 M and 
10-7 M) (one-way ANOVA or Kruskal-Wallis test if not normally distributed, the Newmann-Keuls Multiple 
Comparison Test served as post hoc test; * < 0.05).  
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Inhibitory responses after ghrelin and HM01 superfusion 
 
One of the recorded neurons (6%) was inhibited by the application of both ghrelin and 
HM01 (Figure 34). The inhibitory effect of ghrelin started with a latency of 337 s and 
lasted for 709 s, whereas the inhibition after superfusion with HM01 started after 115 s 
and lasted for 4131s. 
 
 
Figure 34: Recording of the ArcM neuron, which was inhibited after the application of ghrelin (10-8 M) and 
HM01 (10-6 M). 
 
Repeated stimulation with HM01  
 
In previous studies electrophysiological studies repeated superfusion of ghrelin did not 
lead to reduced neuronal sensitivity (Traebert et al., 2002). To evaluate whether this is 
also true for the ghrelin agonist 7 cells were repeatedly stimulated with HM01 at both 
concentrations. All of these cells were excited after the first application of ghrelin and 
HM01. In 4 recordings the repeated superfusion of HM01 induced excitatory responses 
(Figure 35). The absolute mean responses after the second stimulation with HM01 10-7 M 
were significantly reduced (p = 0.017) (Figure 36). In 3 of the repeatedly stimulated cells 
no further response occurred after the subsequent superfusions with HM01 (Figure 37). 
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To test if the loss of sensitivity was specific for the ghrelin receptor or might reflect a 
general loss of excitability we superfused glucagone-like-peptide-1 (GLP-1). As shown 
in Figure 37, GLP-1 elicited an excitatory response despite the loss of HM01 sensitivity 
before and after superfusion of GLP-1. Hence, the repeated stimulation with HM01 does 
not seem to exert a generalized loss of responsiveness to hormonal stimuli. Moreover, it 
is unlikely that the loss of responsiveness was due to the higher dose HM01 (10-6 M) 
since we had repeated responses in one cell tested at this concentration (data not shown). 
 
Figure 35: Recording of an ArcM neuron repeatedly stimulated with ghrelin (10-8 M) and HM01 (10-7 M). 
Not only the first application of ghrelin (10-8 M) and HM01 (10-7 M), but also their subsequent superfusions, 
led to excitatory responses. 
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Figure 36: Mean absolute response of the excitatory effects after HM01 superfusion of the cells repeatedly 
stimulated wit HM01 (10-7 M). The mean absolute response after the second stimulus with HM01 was 
significantly smaller if compared to the mean absolute response of the second one. Data were analyzed with 
the student’s t-test, p = 0.017 
 
 
Figure 37: Representative recording of an Arc neuron, which shows excitatory responses after ghrelin (10-8 
M) and the first HM01 (10-6 M) superfusion. No change in neuronal activity was seen after the second and 
third application of HM01 (10-6 M). GLP-1 (10-7 M) led to an excitatory response. 
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6.6 Effect of the ghrelin agonist HM01 on food intake and body weight 
in rats 
In order to investigate the effect of chronic HM01 treatment on food intake and body 
weight, rats were divided in two groups. Animals of the control group were implanted 
with an osmotic minipump filled with saline, whereas the treatment group received 
minipumps filled with the ghrelin agonist HM01 (10 µg/µl, pump rate 50 µg/h). HM01 
potently and significantly stimulated food intake starting from the first day after 
minipump implantation (Figure 38). This effect remained stable during the 12 days of 
measurements. On average the HM01-treated rats consumed about 6-7 g (20-30 %) more 
food than the controls. HM01 treatment significantly increased cumulative food intake 
(12-day cumulative food intake: HM01, 405 ± 6 g; saline, 329 ±7 g. (Figure 39). The 
HM01-induced increase in food intake was paralleled by an increase in body weight 
relative to controls, which became significant from day 5 after minipump implantation 
(Figure 40). At the end of the experiments the difference in body weight was about 35 g 
(HM01 treated group 369 ± 6 g vs controls 334 g ± 8 g). HM01 treated animals gained 
27.6% of their initial body weight, whereas controls gained only 17.6% of the initial body 
weight (p = 0.0014).  
 
 
 
Figure 38: Daily food intake of HM01 (red) and saline (black) treated rats. Data were analyzed using the 
student’s t-test (**p < 0.01, *** p < 0.001) 
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Figure 39: Cumulative food intake of HM01 (red) and saline (black) treated rats. Data were analyzed using 
the student’s t-test (*** p < 0.001) 
 
Figure 40: Body weight of HM01 (red) and saline (black) treated animals. Data were analyzed using the 
student’s t-test (*p < 0.05) 
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7 Discussion 
7.1 Central neuroinflammatory pathways involved in sickness anorexia 
7.1.1 Involvement of NF-κB and JAK/STAT pathways in the LPS/NO-
dependent inhibition of neurons in the arcuate nucleus 
In previous immunohistochemical and electrophysiological studies the inhibitory effects 
of LPS and the nitric oxide donor SNP on orexigenic Arc neurons have been 
demonstrated (Becskei et al., 2008; Riediger et al., 2010; Riediger et al., 2006). 
Subsequent studies have shown that this inhibition is mediated through stimulation of 
endogenous iNOS-dependent NO production (Borner et al., 2012). However, the 
signaling pathways involved in the iNOS dependent NO effects in the Arc under 
inflammatory condition have not been analyzed yet.  
 
The current study provides electrophysiological evidence that the NF-κB signaling 
pathway is involved in the LPS induced iNOS dependent effects in the Arc. In contrast, 
JAK2-dependent STAT phosphorylation does not seem to be essential for LPS-induced 
NO effects in the Arc at least under our experimental in vitro conditions. 
The results of the immunohistochemical experiments of this study show a pSTAT3 but 
not pSTAT1 formation in the Arc after 4 h in vitro LPS stimulation. Although activation 
of the NF-κB pathways tended to be higher in the Arc 2 hours after LPS in vivo 
stimulation compared to controls, these differences did not reach statistical significance. 
Moreover, we characterized the cells with nuclear NF-κB as endothelial cells using the 
endothelial marker von Willebrand factor. 
 
Electrophysiological studies  
 
The involvement of NF-κB in the transcriptional regulation of iNOS expression has been 
described in rat (Eberhardt et al., 1998), mouse (Xie et al., 1994) and human (Marks-
Konczalik et al., 1998) cell lines. We used an electrophysiological approach to examine 
the role of the transcription factor NF-κB in the LPS-induced NO effects in the Arc under 
inflammatory in vitro conditions.  
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To evaluate the LPS-induced NO-dependent inhibition of orexigenic Arc neurons, we 
tested 1400W-responsiveness of Arc neurons after LPS incubation. Similar to previous 
electrophysiological studies (Borner et al., 2012), 1400W induced excitatory responses 
under these inflammatory conditions. Furthermore, there was a high degree of co-
sensitivity for 1400W and ghrelin because 60% of all tested neurons were excited by both 
stimuli. These findings further substantiate an iNOS/NO-mediated inhibition of 
orexigenic Arc neurons by LPS. 
Our results show a significantly decreased number of 1400W-excited neurons after NF-
κB blockade whith Bay 11-7085. This lack of responsiveness was not due to NO 
insensitivity as confirmed by the sensitivity to the NO donor SNP. Although the number 
of excited neurons after superfusion of 1400W was clearly higher in the LPS stimulated 
positive control group (80%), one of the recorded neurons (10%) was sensitive to 1400W 
after co-incubation with Bay 11-7085. Whether the persistence of 1400W responsiveness 
might reflect NF-κB-independent NO signaling has not been specifically investigated 
owing to the low incidence of such responses. An alternative explanation might be an 
incomplete inhibition of NF-κB. The NF-κB inhibitor Bay 11-7085 was used at a 
concentration of 1 µM and its reported IC50 values are in the range of 5-10 µM (Pierce et 
al., 1997). However, previous studies demonstrated an effect of Bay 11-7085 on mouse 
leukemia cell lines already at concentration of 0.14 µM (Cory and Cory, 2005). For this 
reason the first hypothesis (NF-κB-independent NO signaling) appears more likely. In 
this context it is also important to note that superfusion of Bay 11-7085 did not affect 
neuronal activity in any of the 10 tested neurons, indicating the absence of any effects 
that would interfere with neuronal function. 
In conclusion these findings are in line with the pivotal role of NF-κB in iNOS regulation. 
They provide the first functional evidence for the involvement of NF-κB in the LPS-
induced NO dependent inhibition of orexigenic Arc neurons. 
 
Using a similar electrophysiological approach we also examined the involvement of 
JAK2 in the LPS-induced iNOS-dependent NO production in the Arc during 
inflammation. After blocking JAK2 phosphorylation with the JAK2 inhibitor WP1066 
we still observed excitatory 1400W effects in 25% of all tested neurons. Although this 
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percentage of sensitive cells was considerably lower than under positive control 
conditions (63%), this difference did not reach statistical significance. In contrast to Bay 
11-7085, superfusion of the JAK2 inhibitor WP1066 induced both excitatory and 
inhibitory effects in the Arc. The underlying cellular mechanisms of these effects remain 
unknown. Due to the short onset of these responses any effects that are based on 
alterations of gene expression are unlikely. We used an effective concentration of 
WP1066, which was 2-fold higher than the IC50 (Iwamaru et al., 2007). There was no 
indication that the 4 h incubation with WP1066 might have compromised neuronal 
function, which could for example be reflected by a loss of neuronal excitability in 
general.  
Based on our findings, JAK2 dependent STAT1 and STAT3 phosphorylation does not 
seem to be essential for the LPS/NO-mediated effects in the Arc at least under the current 
experimental in vitro conditions. In light of the well-known role of STAT signaling in 
iNOS gene expression the persistence of LPS/NO signaling after JAK2 blockade might 
appear surprising. However, these results do not rule out an involvement of STAT 
signaling in LPS/NO in vivo. In contrast to in vivo LPS treatment, a systemic cytokine 
response does not occur under in vitro conditions. While a local cytokine production in 
the Arc has been demonstrated after LPS treatment (Konsman et al., 2004), the Arc 
intrinsic production of cytokines has not yet been investigated after in vitro stimulation 
with LPS. Due to the multitude of interacting inflammatory mediators induced by LPS in 
vivo, the inflammatory impact on the Arc might be higher after in vivo than under in 
vitro conditions. While LPS is known to directly activate the NF-κB pathway (Aktan, 
2004; Gao et al., 1998), the JAK2/STAT is mainly activated by cytokines. Although 
many different cytokines activate the same JAKs (Imada and Leonard, 2000), there are 
different JAK/STAT pathways, which are activated through specific cytokines. For 
example, IFNγ has been shown to lead almost exclusively to STAT1 activation 
(Aaronson and Horvath, 2002; Meraz et al., 1996; Tedeschi et al., 2003). It is not known 
if IFNγ is produced in the Arc following in vitro LPS stimulation. A partial inhibitory 
effect of WP1066 seems unlikely, since we used a 2-fold higher dose of the reported IC50 
for WP1066 (Iwamaru et al., 2007). 
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NF-κB and STAT signaling cascades interact to regulate iNOS gene transcription. 
Interestingly both pathways appear to have specific activators (Gao et al., 1998). In fact, 
co-stimulation of mouse macrophages with LPS and INFγ leads to increased NO 
production if compared to stimulation with LPS alone, suggesting that iNOS expression 
levels are synergistically augmented by the combination of LPS and INFγ (Lorsbach et 
al., 1993; Lowenstein et al., 1993). Based on the model that LPS/NF-κB and 
IFNγ/STAT1 pathways seem to act synergistically to regulate iNOS-dependent NO 
production (Figure 41) our demonstration of NF-κB-mediated iNOS signaling in vitro 
might only reflect activation of the direct LPS-dependent pathway. Because of the 
absence of a peripheral cytokine response the IFNγ- or cytokine-dependent pathway is 
likely to be less activated in vitro, which could explain why the blockade of JAK2/STAT 
pathway did not significantly affect LPS/NO signaling in our study. This assumption 
might be supported by future electrophysiological studies using IFNγ or other cytokines 
activating the STAT1 pathway. 
 
Figure 41: iNOS activation through LPS/NF-κB and IFNγ/STAT1 signaling pathways (From Aktan, 2004 
modified by T. Borner) 
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Immunohistological studies 
 
STAT1 and STAT3 phosphorylation in the Arc in response to LPS injection in vivo have 
been shown in several immunohistochemical studies (Gautron et al., 2002; Riediger et al., 
2010; Rummel et al., 2005). In the present study 4 h after in vitro LPS stimulation a 
pSTAT3 formation in the Arc of rats was shown. However, no significant difference if 
compared to the control group was found for STAT1 phosphorylation. The absence of a 
pSTAT1 response seems to support the electrophysiological observation that the LPS-
induced NO responses in vitro are independent of JAK2/STAT signaling. The detection 
of pSTAT3 is not contradictory to the electrophysiological outcome because pSTAT3 is 
likely to be involved in iNOS independent signaling cascades that have not been 
specifically investigated in this study (e.g. expression of neuropeptides, inflammatory 
mediators) (Bates and Myers, 2004). However, several considerations should be to taken 
into account for the interpretation of the immunohistological findings, particularly in 
relation to previous studies reporting LPS-induced pSTAT1 and pSTAT3 responses in 
vivo. 
While the in vitro pSTAT3 response is in line with the reported in vivo STAT3 responses 
in mice, the LPS-dependent STAT1 phosphorylation in the Arc has only been reported in 
vivo (Borner et al., 2012) but not in vitro (current study). One possible explanation for 
the lacking STAT1 phosphorylation in vitro might be the absence of an activating 
stimulus for STAT1 under these in vitro conditions. Under in vivo conditions circulating 
cytokines play an important role. As mentioned above, although many different cytokine 
activate the same JAKs (Imada and Leonard, 2000), there are different JAK/STAT 
pathways, which are selectively activated through specific cytokines. For example type I 
interferon (IFNα/β) activates STAT1 and STAT2, while type II interferon (IFNγ) almost 
exclusively leads to STAT1 phosphorylation. Therefore the absence of a pSTAT1 
response in the current study indicates that LPS alone does not seem to be sufficient for 
an activation of the STAT1 pathway in the Arc. Notably, this finding does not rule out 
the possible importance of LPS dependent STAT1/iNOS signaling in vivo, because LPS 
induces an IFN response by interacting with immune cells. 
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There are also experimental aspects that need to be considered. Under in vitro conditions 
a phosphorylation of STAT1 might occur at a different time point than after in vivo LPS 
stimulation. Hence it might be interesting to analyze both earlier and later time points 
after LPS in vitro stimulation. Furthermore, the lack of a pSTAT1 response in vitro might 
be due to other stimuli that potentially mask an LPS induced STAT1 phosphorylation. In 
contrast to our in vitro studies, basal pSTAT1 formation was low in saline treated control 
mice (Borner et al., 2012) whereas we found considerable basal STAT1 activation under 
control condition in vitro. Although species differences might also account for 
differences in basal pSTAT1, the mechanical stimulation of Arc sections during the 
preparation and subsequent incubation might increase STAT1 phosphorylation via local 
inflammatory or non-inflammatory mechanisms. It is difficult to control for such 
influences, which could override a specific LPS effect on STAT1 phosphorylation.  
 
Despite the clear electrophysiological evidence for an involvement of NF-κB in the 
LPS/NO-dependent modulation of neuronal Arc activity, the immunohistological studies 
did not provide further evidence for a significant activation of the NF-κB pathway in the 
Arc under the current testing conditions after in vivo as well as in vitro LPS stimulation. 
For our immunohistochemical study we used an anti-NF-κB antibody directed against the 
p65 subunit. This antibody has been evaluated for specificity and reported to be the most 
reliable antibody to detect NF-κB immunoreactivity in the brain (Herkenham et al., 2011). 
Inactive NF-κB is located in the cytosol of unstimulated cells as homo- or heterodimers, 
usually comprising p50 and p65, bound to IκB proteins. 
iNOS gene expression in the Arc peaks between 2 and 6 hours after peripheral LPS 
administration (Wong et al., 1996). This time course parallels the anorectic response to 
LPS that usually starts between 2 and 6 hours (Langhans et al., 1991; Langhans et al., 
1993). Based on these findings, we examined NF-κB activity in the Arc 2 and 4 hours 
after LPS injection in rats. Furthermore, we included an 1 hour time point after in vitro 
incubation of Arc slices in order to detect possible direct effects of LPS that might occur 
early and independent of immune cell responses. To differentiate between nuclear and 
cytoplasmatic localization of NF-κB immunoreactivity we performed a Nf-κB-DAPI 
double staining.  
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4 hours after LPS injection NF-κB immunoreactivity was present in structures that 
resembled blood vessels, and small-diameter round cells spread through the parenchyma. 
At the 4 h time point there was no nuclear translocation of NF-κB immunoreactivity in 
LPS and saline treated groups. 
A possible explanation for the lack of NF-κB activation 4 hours after LPS injection is an 
earlier response that is not detected anymore 4 h after LPS injection. This is supported by 
other studies characterizing temporal pattern of NF-κB activation. NF-κB controls the 
expression of IκBα creating a feedback loop in which newly synthesized IκBα binds to 
the nuclear NF-κB exporting it back to the cytosol (Brown et al., 1993; Nelson et al., 
2004a; Sun et al., 1993). Therefore, expression of IκBα has also been postulated to reflect 
the activity of NF-κB (Quan et al., 1997). In situ hybridization studies conducted by 
Quan et al. in the rat brain after peripheral LPS administration have shown different 
spatiotemporal patterns of IκBα expression. An increase of IκB-mRNA-positive cells 
was first seen already 0.5-1 h post injection in cells positioned at the blood side of the 
BBB. After 1 hour, activation in endothelial cells and some astrocytes occurred 
throughout the entire brain with the highest IκBα activity observed in the 
circumventricular organs and the choroid plexus. This response peaked after 2 hours and 
declined afterwards (Quan et al., 1997). However, in this study a septic dose of LPS (2.5 
mg/kg) was used, which was much higher as the one used in the current study (100 
µg/kg). In a subsequent study, Quan et al. examined the induction of IkBα-mRNA after 
peripheral injection of subseptic doses of LPS ranging from 0.01 to 1000 µg/kg. 
Significant induction of IκBα mRNA expression was seen at 2 hours time point in CVOs 
(organum vasculosum of the lamina terminalis, subfornical organ) and blood vessels 
already after injection of small doses of 0.1 µg/kg LPS. The high dose (1 mg/kg) LPS 
induced a different pattern of IκBα mRNA expression. In fact, only the high dose induced 
the expression of IκBα in the brain parenchyma, beyond the CVOs and blood vessels 
(Quan et al., 1999). Hence, in our studies the NF-κB response could have peaked at an 
earlier time point, or the dose we used could have been to low to observe an NF-κB 
activation under our experimental conditions and with the used techniques. Based on the 
findings of the aforementioned studies of Quan et al. we performed a second experiment 
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at an earlier time point (2 hours) and injected LPS at two different doses (100 and 300 
µg/kg). Moreover, an endothelial marker was used to identify blood vessels in the Arc.  
2 hours after LPS injection NF-κB immunoreactivity was seen in the Arc in each of the 
three groups (saline, 100 and 300 µg/kg LPS). At this time point we were able to identify 
nuclear translocation of NF-κB in some cells, which were identified as endothelial cells 
due to their vWF immunoreactivity. In non-vascular cells of the brain parenchyma NF-
κB immunoreactivity was confined to the cytoplasm and no nuclear translocation was 
observed. Despite the observed nuclear translocation of NF-κB no significant difference 
in the number of cells with activated NF-κB was found between the three treatments 
(saline, 100 and 300 µg/kg LPS). Together with the previously reported studies of Quan 
et al. these findings might suggest that NF-κB activation peaks at an earlier time point 
than 4 hours. Obviously, we cannot exclude the possibility that a significant activation of 
the NF-κB pathway might occur at other time-points than 2 and 4h post stimulation.  
 
We further investigated if NF-κB activation occurs after 1 hour in vitro LPS stimulation 
of Arc slices. NF-κB immunoreactivity was seen in each group and a high number of 
cells with nuclear NF-κB staining was observed. However, no significant difference 
between the LPS-stimulated Arc sections was found in comparison to controls. NF-κB 
activation was present in cells spread through the parenchyma, as well as in cells in close 
vicinity to blood vessels. Since this high number of cells that showed NF-κB nuclear 
translocation was present in both groups, we assume that a possible activation of NF-κB 
signaling by LPS might have been masked by the high baseline activation observed under 
these experimental conditions. Irrespective of the reason for this high baseline activation, 
a detection of a specific LPS-mediated effect on NF-κB nuclear translocation might be 
masked under the current in vitro conditions. 
 
A general aspect important to consider when studying the NF-κB pathway, is the fact that 
an oscillatory activation of this transcriptional factor has been demonstrated. Using 
fluorescence imaging techniques and EMSA nuclear-cytoplasmatic oscillation of NF-κB 
in different type of cell cultures after stimulation with inflammatory cytokines such as 
TNF-α was observed (Hoffmann et al., 2002; Nelson et al., 2004a). IκBα is a 
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transcriptional target of NF-κB, and creates a feedback loop transporting NF-κB back 
from the nucleus to the cytoplasm. This negative feedback was shown to induce 
oscillatory nuclear NF-κB activity (Hoffmann et al., 2002; Nelson et al., 2004b). With 
our experimental design the investigation of different time points within the same animals 
is not possible. Moreover, it might be difficult to detect oscillatory differences between 
short time intervals with sufficient temporal resolution in this kind of in vivo experiments, 
also considering the possible inter-individual variability arising from the necessity to use 
different experimental animals for each time point. For these reasons the detection of 
such oscillatory activation is much more difficult to investigate compared to cell culture 
experiments allowing real-time detection NF-κB immunoreactivity within the same cells. 
Consequently other techniques might be required to further investigate NF-κB activation 
under our experimental conditions. A possible approach would be Western blot analysis 
of hypothalamic tissue analyzing cytoplasmatic and nuclear fractions of the NF-κB 
protein. Moreover, an approach based on in-situ mRNA hybridization to detect IκBα-
mRNA might shed more light on NF-κB activation under our experimental conditions. 
 
7.1.2 NF-κB signaling pathway in the area postrema after LPS stimulation in 
vivo 
Several observations suggest an activation of the AP during systemic inflammation. In 
fact, neuronal activation occurs in the AP after immune-challenge with LPS or IL-1 
(Brady et al., 1994; Sagar et al., 1995). Moreover, the AP is involved in sickness anorexia, 
since it plays a role in TNF-α and tumor anorexia (Bernstein et al., 1991; Bernstein et al., 
1985). In a recent study from our group, surgical removal of the AP prevented tumor-
anorexia and body weight loss (Borner T., 2012) However, knowledge about the 
mechanisms involved in activation of the AP during inflammation is lacking. In situ 
hybridization of IκBα mRNA showed that non-septical LPS doses seems to activate NF-
κB signaling mainly in structures non protected by the BBB, namely in CVOs and blood 
vessels (Quan et al., 1999). Unfortunately the AP was not included in this study. The 
presence of NF-κB signaling in the AP was shown in a subsequent study, in which 
nuclear translocation of NF-κB was observed in the AP after immune challenge with IL1-
 Page 75 
β (Nadjar et al., 2003). However they did not quantify the number of cells with activated 
NF-κB.  
In the current study we demonstrated that LPS significantly increases nuclear 
translocation of NF-κB in the AP at both tested doses (100 µg/kg and 300 µg/kg). No 
difference was observed between the group treated with the lower (100 µg/kg) and the 
higher dose (300 µg/kg) of LPS. Using an antibody against rat RECA-1 as endothelial 
marker, most of the cells with activated NF-κB were identified as endothelial cells. Not 
all the cells with nuclear NF-κB co-expressed RECA-1. Interestingly, these non-
endothelial cells with activated NF-κB were located in close vicinity to vascular 
structures. The phenotype of these cells remains to be identified.  
iNOS is expressed in the AP under inflammatory conditions (Konsman et al., 1999) and 
iNOS inhibition reduces neuronal activation in the AP during sepsis (Bruhn et al., 2009). 
Although NF-κB is known to regulate iNOS expression, it remains to be elucidated if the 
LPS-induced activation of the NF-κB pathway observed in the current study in the AP 
leads to iNOS signaling. Whether this pathway is also activated during chronic disease 
conditions associated with anorexia also remains to be determined. Apart from a possible 
modulation of ingestive behavior, the AP seems to mediate LPS-induced behavioral 
depression, such as social withdrawal (Marvel et al., 2004). Hence, the NF-κB pathway 
might play a role in the transduction of immune-related signals relevant for the induction 
of such behavioral responses. However, further experiments are needed to better 
understand these mechanisms.  
 
 
7.2 Electrophysiological and in vivo studies with the synthetic ghrelin-
agonist HM01 
In this study we provide the first in vitro electrophysiological characterization of the new 
synthetic ghrelin agonist HM01. In order to analyze the effects on neuronal activity of 
this compound, the co-sensitivity of Arc neurons for ghrelin and HM01 was analyzed. In 
addition, the effects of chronically administered HM01 on food intake and body-weight 
in healthy rats were investigated during a 12 day period.  
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In the electrophysiological experiments HM01 and ghrelin showed a completely 
concordant response profile in all of the 17 tested neurons. These results demonstrate that 
under in vitro experimental conditions, HM01 mimics the effects of ghrelin on neuronal 
activity of ArcM neurons. Similar to our previous electrophysiological studies from 
medial Arc neurons (Borner et al., 2012; Riediger et al., 2003), ghrelin, and in this case 
also HM01, predominantly induced excitatory responses (76%).  
We performed recordings using two concentration of HM01 (10-6 M and 10-7 M). We 
observed a significant longer response duration after superfusion of the higher 
concentration of HM01 (10-6 M) in comparison to ghrelin. Additionally, application of 
the lower concentration of HM01 (10-7 M) led to a significant longer latency period of the 
excitatory effects if compared to ghrelin and HM01 (10-6 M). However, no difference was 
seen in the absolute response and the peak response. The lack of a concentration-
dependence of these effects for part of the effect parameters might be related to the fact 
the used concentrations reside in the upper range of the concentration-response curve of 
HM01. Although dose-response characteristics may vary between different assays this 
assumption appears plausible considering the EC50 of 1-2 nM for HM01 (unpublished 
observations). However, it was not the aim of this study to establish a complete dose-
response characteristic for the excitatory effects of HM01. Such measurements are more 
relevant for endogenous hormones and the related question whether physiological 
hormone levels might reach the threshold required for neuronal activation.   
Although it as been shown in electrophysiological studies that repeated stimulations with 
ghrelin do not lead to reduced neuronal sensitivity (Riediger et al., 2003), we investigated 
possible desensitizations by repeated stimulation with HM01 stimulating 7 neurons. In 4 
of these cells we observed excitatory responses after the subsequent superfusions of 
HM01 (10-6 M, 10-7 M). However, the absolute response of the second excitatory effect 
of HM01 was significantly reduced after the second superfusion with HM01 10-7 M. In 
the remaining 3 neurons no further response occurred after the second superfusion with 
HM01. In order to exclude a reduced general responsiveness, an additional stimulus 
acting on a different receptor than ghrelin receptor was set. In fact, GLP-1 was still 
effective to induce an excitatory response demonstrating that the general neuronal 
excitability has not been affected by HM01. A possible explanation for the observed loss 
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of responsiveness for HM01 after the first stimulation might be a desensitization of the 
growth hormone secretagogue receptor (GHS-R) itself or of the intracellular signaling 
cascade coupled to the receptor. However, as discussed below, this desensitization did to 
translate into desensitization in vivo at least under the current experimental conditions.  
 
Immunhistochemical and electrophysiological studies suggest that the orexigenic effect 
of ghrelin is mediated via stimulation of NPY/AgRP neurons located in the ArcM of rats 
(Riediger et al., 2003; Traebert et al., 2002; Willesen et al., 1999). Therefore, the ghrelin-
like action of HM01 on neuronal activity in the ArcM is in line with the orexigenic effect 
of HM01 observed in the current study. HM01 treatment in healthy rats was associated 
with increased body weight gain. HM01 strongly stimulated food intake already starting 
from the first day after minipump implantation. In a similar study Strassburg et al. tested 
the metabolic effects of long-term treatment with ghrelin and the GHS-R agonist BIM-
28131. The substances were administered using subcutaneous osmotic minipumps for 4 
weeks. Both led to substantially elevated body weight gain compared with control. 
However, BIM-28131 appeared to be the most potent compound regarding its potency to 
increase body weight. In fact, body weight of the animals receiving BIM-28131 was 
significantly higher than that of ghrelin treated animals (Strassburg et al., 2008). The 
mean increase of body weight after 2 weeks of treatment with BIM-28131 was 
comparable to what we observed in the current study after 12 days treatment with HM01. 
After 2 weeks of BIM-28131 administration the mean daily food intake was 31 ± 1 g vs. 
26 ± 1 g in controls. Likewise, we show that after 12 days of HM01 administration the 
mean food intake was 31 ± 2 vs. 25 ± 1 in controls.  
Interestingly, although we observed a desensitization of the electrophysiological 
responses of HM01, we did not observed any attenuation in the feeding stimulating effect 
of HM01 during the whole testing period. It is not possible to directly compare the 
concentrations of HM01 between the electrophysiological and in vivo studies. However, 
the concentration of HM01 in the brain during chronic HM01 administration at the used 
dosage is presumably lower than the superfused concentration during the 
electrophysiological recordings. Since receptor desensitization can result from excessive 
receptor stimulation the lack of such an effect under the current vivo condition might be 
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due to the lower concentration of HM01 at the receptor. This is indicative of a sufficient 
therapeutic or pharmacological window, in which an effect on food intake occurs in the 
absence of undesired desensitizing actions.   
Based on the longer half-life time and higher metabolic stability, synthetic ghrelin 
mimetics (Akamizu et al., 2004; Blum R, 2006; Nass et al., 2008), are effective in a daily 
single treatment regimen, which is beneficial for their use a anti-anorectic drugs. In a 
recent study the novel ghrelin agonist Anamorelin was tested in patients with cancer-
related cachexia. The half-life of Anamorelin (7 to 12 hours) is much longer compared to 
ghrelin (Blum R, 2006), allowing for a once-a day oral administration. Currently, 
Anamorelin is the only ghrelin-based drug that is in clinical phase III studies for the 
treatment of cancer ACS. This compound was well tolerated and demonstrated significant 
appetite stimulation in healthy volunteers (Garcia and Polvino, 2007). Oral Anamorelin 
treatment for 12 weeks in cachectic patient significantly increased mean lean body mass 
and total body mass when compared to placebo (Garcia JM, 2007). 
Apart from their effects on energy homeostasis ghrelin and ghrelin mimetics are 
supposed to exert further beneficial actions in the context of inflammatory diseases. 
Ghrelin exerts anti-inflammatory actions because it reduces the production of pro-
inflammatory cytokines, which are also elevated during sickness anorexia (Dixit et al., 
2004). Furthermore, in vitro studies postulated an anti-inflammatory effect of ghrelin 
through an inhibition of NF-κB activation (Li et al., 2004). An additional effect of ghrelin 
is the stimulation of growth hormone secretion, which leads to an increase of IGF-1 
levels (Takaya et al., 2000). Since IGF-1 levels are low under cachexia, ghrelin treatment 
could reverse this response leading to an improvement of anabolic functions (Morley et 
al., 2006). Whether any of these effects might contribute the possible therapeutic effects 
of ghrelin-beased approaches will be investigated in follow up studies.  
In summary, based on the results of the current study HM01 treatment qualifies as a 
promising drug candidate for the treatment of ACS.  
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8 Perspectives 
Therapy with ghrelin agonists appears to be a promising approach in the management of 
chronic sickness anorexia. However, it seems that under cancer ACS ghrelin 
responsiveness is reduced, which could limit therapeutic approaches with ghrelin or 
ghrelin receptor agonists. The exact mechanism underlying this reduced ghrelin effects is 
still unknown. Our previous and current demonstration that NO signaling inhibits the 
target cells of the orexigenic hormone ghrelin suggest a direct link between inflammatory 
NO signaling and decreased ghrelin responsiveness. Blockade of iNOS activity appears 
to be a promising strategy for the treatment of disease-related anorexia either as single 
drug treatment or in combination with other anti-anorectic agents. The current studies 
shed more light on the intracellular signaling mechanisms implicated in LPS/NO 
dependent modulation of hypothalamic arcuate neurons involved in energy homeostasis 
suggesting that inhibitors of inflammatory transcription pathways might be therapeutic 
options for the treatment of the anorexia-cachexia syndrome.  
The use of synthetic ghrelin mimetics instead of ghrelin appear to be an interesting 
approach in treatment of human ACS, given the longer half-life and the much more 
practical possibility of the route of administration. Therefore a combination treatment 
with GHS-R agonists and inhibition of NO signaling might improve treatment outcome. 
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